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Summary 
Metastasis is the major cause of death of cancer patients. Accumulating evidence 
suggest that metastatic dissemination is an early event. The presence of 
disseminated cancer cells (DCCs) in patients has been shown to increase the risk of 
disease recurrence. How the DCCs survive, the underlying factors or events that 
awaken DCCs are currently discussed and investigated and are fundamental to the 
understanding of cancer biology. This thesis explores the possibilities to propagate 
DCCs in vitro, and generate cell lines which could later be used for such functional 
studies.  
At first, patient-derived prostate tumor tissue was used to identify in vitro conditions 
for propagating prostate tumor cells as spheres. Later these conditions were used to 
propagate bone marrow (BM)-derived DCCs from prostate cancer patients. Although 
the prostate tumor cells grew as spheres BM-DCCs failed to grow under these 
conditions. A similar observation was made in BALB-neuT mice, a breast cancer 
model. However, the sphere conditions for culturing mammary epithelial cells were 
first optimized with cytokines HIL-6 (hyper IL-6) and GRO-α (growth related 
oncogene α) which were shown to induce proliferation. In addition, DCC density was 
increased by enriching DCCs with antibodies against EpCAM, Her2 and Sca-1 
(EHS). However, these conditions failed to initiate proliferation in DCCs. These 
results indicated that the conditions optimal for generating mammospheres from MEC 
were not optimal for DCC culture. Examining the effect of BM cells on primary tumor 
cells suggested that BM cells exerted a suppressive effect. Reduction in the sphere 
forming efficiency of tumor cells in medium conditioned by BM of normal or tumor 
bearing mice suggested a role for BM cell secreted factors in tumor cell growth 
suppression. On the other hand, primary tumor cells had a growth-promoting effect 
on BM-DCCs. Tumor cells were able to induce growth of DCC derived spheres in 
direct co-cultures through intercellular interactions and in transwells through secreted 
factors. The DCC derived spheres were tumorigenic in vivo and the tumor cells 
isolated from these tumors could further be expanded in vitro as cell lines. The 
tumors and the DCC cell lines expressed CK8/18 and Her2 and displayed an 
aberrant genomic profile. These cell lines could further be used to elucidate DCC 
biology. 
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1. Introduction 
1.1. Metastasis and disseminated cancer cells 
Metastasis is a leading cause of death in patients suffering from cancer. Cells from 
the primary tumor that disseminate to distant organs are thought to comprise 
metastatic founder cells which later develop into manifest metastasis. Studies have 
shown that the persistence of disseminated cancer cells (DCC) in the bone marrow of 
breast and prostate cancer patients predicted poor survival and an increased risk of 
disease relapse (Weckermann, Muller et al. 2001; Braun, Vogl et al. 2005). In a 
pooled study of patients diagnosed with breast cancer published recently by Janni 
and colleagues, 676 women diagnosed with early stages of breast cancer were 
followed for a median of 89 months with bone marrow (BM) aspirations performed 37 
months after diagnosis (Janni, Vogl et al. 2011). The authors observed that at follow-
up 15.5% (105) of total patients had DCCs and 8% of the total patients had 
metastasis. In patients with metastasis, 35% of them had DCCs in the BM. An 
increase of DCC frequency from 15.5% of total to 35% in metastatic patients 
suggests an enrichment of DCCs in patients with metastasis. This further suggests 
that DCCs contain a population of cells with a potential to metastasize and 
emphasize the importance of DCCs in later arising metastasis. Nevertheless, patients 
with DCCs in BM had a significantly shorter disease free or overall survival. A 
previous study on cytokeratin positive (CK+) DCCs in BM of breast cancer patients 
also made similar observations. (Bidard, Vincent-Salomon et al. 2008). Again the 
presence of DCCs correlated to poorer distant metastasis free and overall survival in 
the patients. Although DCCs originate from primary tumor there exists a genetic 
disparity between them. Studies comparing genomic aberrations between DCCs and 
matched primary tumors showed that DCCs were less aberrant than the primary 
tumors and they shared very few aberrations with them (Schmidt-Kittler, Ragg et al. 
2003). Moreover, studies in both breast cancer mouse models and in human breast 
cancers have shown that metastatic dissemination of cancer cells happen early 
during tumor progression (Husemann, Geigl et al. 2008). The process of early 
dissemination has been suggested in a review through parallel progression model 
(Klein 2009). This model suggests that cancer cells disseminate early, and at the 
time of dissemination the DCCs carry few genetic aberrations compared to primary 
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tumor. The DCCs then accumulate additional aberrations, independent of the genetic 
evolution of the primary tumor which later forms metastasis (figure 1). This early 
dissemination model could explain why many patients even after resection of the 
primary tumor and treatment develop metastasis years after surgery. Although 
cancer cell dissemination is an early and frequent event, successful metastatic 
initiation is accomplished only by a few cells at the distant metastatic site. In BM, 
about 1-10 DCCs per 2 million BM cells can be detected (Klein 2009). Although this 
number is very low, there could be thousands of DCCs when the whole bone marrow 
is considered. Still, only a few manifest metastases arise from these cells suggesting 
that metastatic initiation in most of the cells is inefficient. 
 
 
Figure 1: Models explaining cancer cell dissemination.  
Parallel progression model states that metastatic dissemination occurs at an early stage 
during the development of cancer and evolves along with the primary tumor at distant site 
and later forms overt metastasis even in the absence of primary tumor (Klein 2004). 
1.2. Molecular mechanisms involved in metastasis 
Metastatic dissemination is a multi-step process. First, the cells in the primary tumor 
must attain a migratory phenotype followed by invasion of the local vasculature, 
extravasation at the distant metastatic sites and finally colonize and adapt to the 
surrounding metastatic niche microenvironment before developing into manifest 
metastasis (figure 2) (Nguyen, Bos et al. 2009). For prostate and breast cancers the 
preferred site of dissemination is bone marrow. In mouse models, it has been shown 
that the prostate cancer cells home to bone marrow niches which are traditionally 
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occupied by the hematopoietic stem cells (Shiozawa, Pedersen et al. 2011). Although 
the factors involved in the niche formation are still unknown, chemokine factor 
CXCL12 (Stromal derived factor-1) which interacts through CXCR4 and CXCR7 
receptors, was shown to act as a chemo attractant guiding the DCC to bone marrow 
metastatic niches in breast cancer (Mukherjee and Zhao 2013). Additionally, vascular 
endothelial growth factor (VEGF) in the niche microenvironment has been shown to 
play a role in tumor cell adhesion. (Shiozawa, Pedersen et al. ; Kaplan, Riba et al. 
2005; Kaplan, Rafii et al. 2006). In the bone marrow, VEGFR1+ hematopoietic 
progenitor cells and osteoblasts are shown to initiate pre-metastatic niche formation 
(Kaplan, Riba et al. 2005; Kaplan, Psaila et al. 2007). Although the process of 
dissemination and the DCC niches in the bone marrow are known, the events that 
trigger the switch from quiescence to proliferation or the factors responsible for the 
activation of DCC in the distant metastatic niches years after curative surgery still 
remain elusive. Over the years, identifying factors responsible for the activation of 
DCC has become a challenge and the lack of success has hindered our 
understanding of these cells and events that lead to their activation. Although several 
chemokines (Viola, Sarukhan et al. 2012) and cytokines (Rao, Dyer et al. 2006; Culig 
2011) have been shown to play a role in aiding tumor progression none were shown 
to have a direct impact on DCC activation.  
 
 
Figure 2. Process of metastatic dissemination of cancer cells. 
The cells in the primary tumor first gain a migratory phenotype and later invade the local 
vasculature. Once they reach a distant metastatic site the cells extravasate out of the 
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vasculature into the secondary organ, adapt to the surrounding microenvironment of the 
metastatic niche and later develop into manifest metastasis. (Figure adapted and modified 
from (Allan, Vantyghem et al. 2006-2007)) 
1.3. Detecting circulating and disseminated cancer cells 
Epithelial markers like cytokeratins and epithelial cell adhesion molecule (EpCAM) 
are routinely used to identify and isolate DCC but they might not be efficient in 
capturing all the DCCs. The property  of cancer cells to disseminate from the primary 
tumor site to the distant metastatic site is attributed to their ability to undergo 
epithelial-to-mesenchymal transition (EMT) (Hollier, Evans et al. 2009). Furthermore, 
recent studies have indicated that during EMT these disseminating cells down 
regulate EpCAM suggesting that these cells escape detection methods relying on 
these epithelial markers (Mikolajczyk, Millar et al. 2011; Gorges, Tinhofer et al. 2012). 
Proliferative potential of CTC in the blood has been used as an alternative method to 
identify and isolate these cells on collagen adhesion matrix, in prostate cancer 
patients (Paris, Kobayashi et al. 2009). However, these patients already had 
metastasis implying that the DCCs were already activated and proliferating. It would 
be interesting to see if DCC from non metastatic patients also respond similarly. PCR 
based methods have also been employed in identifying both DCCs and CTCs in 
peripheral blood and BM of cancer patients. RT-PCR has been used to measure the 
mRNA for CK19, CK20 and mammoglobin for identifying breast cancer DCCs 
(Schoenfeld, Kruger et al. 1997; Berois, Varangot et al. 2000; Zhong, Kaul et al. 
2000; Bossolasco, Ricci et al. 2002), PSA for prostate cancer DCCs (Halabi, Small et 
al. 2003) and CEA, MUC1, TIFF in addition to CK20 for gastric cancer DCCs 
(Dardaei, Shahsavani et al. 2011). The problem with RT-PCR based methods is the 
availability of DNA or mRNA in low amounts. Genomic and transcriptomic analysis of 
single DCCs have been established to identify tumor cells based on an aberrant 
genomic profile (Klein, Schmidt-Kittler et al. 1999; Klein, Seidl et al. 2002). This 
method overcomes the problem of low mRNA and DNA amounts encountered in the 
RT-PCR based methods but then, identification of DCCs is still dependant on 
epithelial markers (cytokeratins and EpCAM). However, another problem with PCR 
based methods is that the functional properties of the isolated DCCs cannot be 
evaluated. Since, only a few DCCs are capable of initiating metastasis analyzing their 
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functional capabilities is also important. Therefore, an in vitro model to study DCCs is 
essential.  
1.4. In vitro culture of disseminated cancer cells 
It has been a challenge over the years to propagate DCCs in vitro. This could be due 
to their presence in low numbers or because the conditions to propagate DCCs in 
vitro are still unknown. However, there have been made attempts to culture DCCs in 
vitro. In the studies published by Pantel and colleagues, cell lines were generated 
from DCCs isolated from the bone marrow of prostate, breast, colon esophageal and 
lung cancer patients. However, the possibility of generating DCC cell lines was 
achieved only after immortalizing the surviving DCCs with SV40 large T antigen 
(Pantel, Dickmanns et al. 1995; Putz, Witter et al. 1999; Hosch, Kraus et al. 2000). 
SV40 large T antigen is known to interfere with the general cellular process of a cell. 
It interacts with several cellular pathways to transform and immortalize the cells. 
(Ahuja, Saenz-Robles et al. 2005). These cell lines, as the author states, were not 
assessed for any collateral effects caused by SV40 large T antigen induced 
transformation. SV40 large T antigen is shown to bind to the tumor suppressor 
proteins retinoblastoma family of tumor suppressors and p53 to transform the cells 
(Ahuja, Saenz-Robles et al. 2005). Therefore, the possibility of results from these cell 
lines in various experiments could be mediated via large T antigen and may be 
different to normal cells which do not contain the large T antigen. Thus, it is important 
to expand DCC in vitro without any induced transformation and immortalization. 
DCCs from prostate cancer were shown to occupy hematopoietic stem cell niches in 
the bone marrow (Shiozawa, Pedersen et al. 2011). Moreover, recently in breast 
cancer also it has been shown that DCCs reside in perivascular niches (Ghajar, 
Peinado et al. 2013) and perivascular niches are shown to maintain hematopoietic 
stem cells (Ding, Saunders et al. 2012). This could suggest that the DCCs might 
share some similarities with the stem cells and therefore, may require different 
conditions to propagate them in vitro. In the last decade, in vitro culture techniques 
have been developed to culture stem/progenitor cells. In breast cancer, it has been 
shown that suspension or non adherent cultures enrich for stem/progenitor cells, 
grown as spheres called mammospheres (Dontu, Abdallah et al. 2003). Therefore, it 
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would be worthwhile to test these stem/progenitor enriching in vitro culture conditions 
and see if the bone marrow derived DCCs proliferate in these conditions. 
1.5. The BALB-neuT mouse model 
Since, patient BM derived DCCs are very rare and variable about 1-10 per 2 million 
BM cells (Riethdorf, Wikman et al. 2008), we looked at mouse models where DCCs 
have been reported to be lodging in the BM at a higher frequency. BALB-neuT is a 
transgenic mouse which develops breast cancers and is a commonly used mouse 
model to study breast cancer. Integrated into the genome of the mouse the construct 
consists of a MMTV LTR (Mouse mammary tumor virus, long terminal repeats) region 
which is transcriptionally active, the neuT oncogene and SV40 polyA recognition 
sequence (Muller, Sinn et al. 1988). The origin of the oncogene neuT is from the rat 
and is the corresponding homologue of human Her2. This gene contains a point 
mutation, at position 664 of the amino acid sequence valine is replaced with 
glutamine which induces neuroblastoma in the rat. This mutation is in the 
transmembrane region of the receptor and results in more than 100-fold increase in 
the receptor kinase activity. Moreover this mutant protein is phosphorylated to a 
higher degree when compared to the wild type protein (Bargmann and Weinberg 
1988). The MMTV promoter responds to estrogen and progesterone and is activated 
at the onset of puberty in female mice. Disseminated cancer cells can be identified in 
the bone marrow of BALB-neuT by staining the bone marrow cells with cytokeratin 
8/18 (CK8/18), a marker for epithelial cells. The DCCs in the bone marrow of the 
mice can be identified as early as week 4. The number of DCCs in the bone marrow 
of this mouse is between 4-20 cells per million bone marrow cells. DCCs were 
detected in the bone marrow even before tumor became palpable. In the 
transplanted mouse model, where the recipient wild type mice (BALB/c) received 
orthotropic transplants from their 3-4 week old transgenic siblings (BALB-neuT), 
DCCs were also detected. However, the number of DCCs detected in the 
transplanted mice in comparison to the BALB-neuT was lower. The reason could be 
due to the presence of 10 mammary glands in the transgenic mouse against 1 gland 
from the transgenic mouse in the wild type recipient (Husemann, Geigl et al. 2008). 
Thus, BALB-neuT breast cancer mouse model seemed appropriate for studying 
DCCs in the current doctoral project.  
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Aim of the project 
Disseminated cancer cells have been difficult to culture in vitro. Hence, the 
knowledge about these cells is limited. Although their persistence in patients even 
after surgery is associated with high risk of relapse, the reasons for their activation 
and the factors responsible for their activation is not known. The problems in 
evaluating DCCs are that they are rare, there are no reliable markers for identifying 
them and last but certainly not the least there are no in vitro models to elucidate them 
functionally. Therefore, knowing the conditions to expand them in vitro and availability 
of in vitro models are critical in further evaluating DCCs. 
The aim of this project was to first identify conditions to propagate bone marrow 
derived DCC in vitro, then analyze the functional and molecular characteristics of the 
activated DCCs and finally expand them in vitro to generate cell lines. These cell 
lines could then serve as models for further understanding DCC biology.  
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2. Methods 
2.1. Mouse experiments 
All mouse experiments were performed at the animal facility of the University of 
Regensburg. The application to work with BALB/c and BALB-neuT mice for the 
research projects was approved by the Government of Upper Bavaria (Az.209.1/211-
2531-108/04). 
2.2. Cell culture methods 
2.2.1. Processing patient bone marrow  
After obtaining informed consent from the patient, bone marrow aspirates were 
washed with Hanks buffer salt solution (HBSS) and centrifuged at 200xg for 10 min to 
remove fat and thrombocytes. The supernatant was discarded and cell pellet was 
resuspended in 9 ml of HBSS and slowly added on top of percoll 60% (6 ml) and 
centrifuged at 1000xg for 20 min, to remove erythrocytes and granulocytes. The 
interphase was transferred to a new 50 ml tube. The tube was filled with PBS and 
centrifuged at 500xg for 10 min. The pellet was resuspended in 2-10 ml PBS 
depending on the size of the pellet. Erythrocytes and leukocytes in the percoll 
fraction were counted. The cells were centrifuged at 500xg for 10 min, the pellet was 
resuspended in MACS buffer (90 µl/107 cells) and incubated with anti-CD11b (10 
µl/107 leukocytes), anti-CD33 (5 µl/107 leukocytes) and anti-CD45 (5 µl/107 
leukocytes) antibody conjugated to anti-APC on a roller for 15 min at 4° C. The cells 
were washed by adding 10 volumes of MACS buffer and centrifuged at 500xg for 5 
min at 4° C. The supernatant was removed and the pellet was resuspended in MACS 
buffer (60 µl/107 cells) and incubated with anti-APC-beads (20 µl/107 leukocytes) and 
anti-Gly A beads (20 µl/107 erythrocytes) for 15 min on a roller at 4° C. The cells 
were washed with 10 volumes of MACS buffer and centrifuged for 5 min at 500xg. 
The pellet was resuspended in 2 ml of MACS buffer, filtered through 40 µm mesh to 
remove cell clusters and then loaded onto the magnetic column already equilibrated 
with 3 ml MACS buffer. The tube was washed with 9 ml MACS buffer which was run 
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over the column in aliquots of 3 ml. The cells in the flow-through (11 ml) were 
counted. 
2.2.2. Culturing bone marrow DCC of patients 
After magnetic sorting, 200000 cells/ml were seeded in sphere medium (see 
materials, Media for prostate sphere medium) in a 6 cm dish and incubated for 4 
weeks at 37° C, 5.5% CO2 and 7% O2. The culture dishes were replenished with 1 ml 
of fresh medium every week until the cultures were terminated. The bone marrow 
culture dishes were screened every week for spheres. 
2.2.3. Mammary tissue digestion and epithelial cell isolation 
The mice were killed by asphyxiation with CO2 or by cervical dislocation. Mammary 
glands were collected either from BALB/c or BALB-neuT in a 50 ml tube with PBS. 
The tissue was minced with surgical blades to small pieces and digested in basal 
medium (DMEM/F12, 100 nM HEPES buffer, 10 mg/ml insulin, 0.5% BSA and 0.5x 
penicillin/streptomycin) with 200 U/ml collagenase, 10 ng/ml EGF and 200 U/ml 
hyaluronidase. The tissue was digested for 2-3 hours at 37° C in the incubator mixed 
every 1 hour. The digested tissue was transferred to a 50 ml tube. After a first 
centrifugation step of 1 min at 80xg to isolate the organoids the supernatant was 
collected into a new 50 ml tube and centrifuged at 200xg for 3 min to isolate 
mammary epithelial cells (MEC). Subsequently, the supernatant was transferred into 
a new 50 ml tube and centrifuged at 350xg for 4 min to isolate fibroblasts (figure 3). 
The organoids were either frozen in a freezing medium containing 10% DMSO and 
50% FCS in DMEM/F12 or further digested to isolate single cells. 
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Figure 3: Schematic representation of epithelial cell isolation from murine 
mammary glands.  
The mammary tissue is minced with a scalpel to small pieces, enzymatically digested and 
afterwards epithelial cells are isolated by differential centrifugation at 200xg for 3 min. The 
isolated epithelial cells were later cultured in non-adherent serum-free conditions to generate 
mammospheres.  
 
2.2.4. Preparation of single cells from organoids 
Freshly isolated or frozen organoids were used for isolation of epithelial cells. If 
frozen, the organoids were first thawed and transferred into 15 ml  tube with 4 ml of 
pre-warmed basal medium. The tube was centrifuged at 40xg for 2 min at room 
temperature (RT) and the supernatant was discarded. Fresh or thawed organoids 
were resuspended in 3 ml of trypsin-EDTA and incubated for 1 min at RT. The 
suspension was carefully and slowly mixed for 2 min with a 5 ml pipette along the 
tube wall avoiding formation of bubbles. Then, 5 ml of trypsin neutralizing solution 
(TNS) were added, incubated for 1 min and centrifuged at 300xg for 3 min at RT. The 
supernatant was discarded and the pellet was resuspended in 3 ml of freshly 
prepared dispase (5 mg/ml) and 200 µl of 1 mg/ml DNase solution. The suspension 
was mixed using a 5 ml pipette along the tube wall for 2 min. Additional 200 µl of 
DNase solution was added, if the solution was thick suggesting release of DNA, and 
mixed for another 1 min. The suspension was filtered through a 40 µm mesh to 
remove any large cell clusters. The flow-through was centrifuged at 300xg for 3 min 
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at RT. After washing in 5 ml of 1x PBS the pellet was resuspended in 2-5 ml of PBS 
(depending on the pellet size) and viable cells were counted on a Neubar chamber. 
 
2.2.5. Isolating cells from murine bone marrow 
Tibias and femurs were collected either from BALB/c or BALB-neuT in PBS or basal 
medium. The soft tissue surrounding the bones was removed. One of the bone ends 
was cut with scissors to expose the bone marrow. Using a 26G needle and 1 ml 
syringe the bone marrow was flushed out into a 50 ml tube. Alternatively, for some 
experiments the flushed bones were put into a mortar to break the bones using 
mortar and pestle. The broken bones were washed with 1x PBS to collect the 
remaining bone marrow cells after flushing. Afterwards, the cells were pooled and 
centrifuged at 200xg for 10 min. The supernatant was discarded and the pellet was 
resuspended in 9 ml of 1x PBS. The cell suspension was slowly and carefully 
overlaid onto 6ml of 65% percoll in a 15 ml tube to form a layer and centrifuged for 20 
min at 1000xg to remove erythrocytes. The interphase was then carefully collected 
using a 5 ml pipette and transferred into a new 50 ml tube. The tube was filled up 
with 1x PBS and centrifuged for 10 min at 500xg for washing the cells. The cells were 
resuspended in 5 ml of 1x PBS and counted. 
 
2.2.6. Enrichment of bone marrow DCC 
The bone marrow cells were enriched for EpCAM, Her2 and Sca-1 (EHS) after 
density centrifugation. After counting, the cells were centrifuged for 10 min at 400xg.  
Supernatant was discarded and the cell pellet was resuspended in MACS buffer (100 
µl / 107 cells). Primary antibodies anti-EpCAM-bio (10 µg/ml), anti-Her2 (10 µg/ml) 
and anti-Sca-1-FITC (10 µl/107 cells) were added and incubated for 15 min at 4° C on 
a roller. After incubation, 10 volumes of MACS buffer were added and centrifuged for 
10 min at 400xg. Supernatant was discarded and the pellet was resuspended in 4 
volumes of MACS buffer containing anti-biotin, anti-IgG2a+b and anti-FITC magnetic 
microbeads and incubated for 15 min at 4° C on a roller. After incubation 10 volumes 
of MACS buffer was added and centrifuged for 10 min at 400xg. The procedure for 
sorting the cells on the columns is as explained in 2.2.1. All cells bound by magnetic 
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microbeads stick to the magnetic column and the rest flow though the column. After 
carefully transferring the column with positive fraction to a 15 ml tube, 5 ml of MACS 
buffer were added to the column and cells were flushed out into the tube. The 
negative fraction was again run through the column and the positive fraction collected 
in the tube with the 1st positive fraction. 
 
2.2.7. Sphere forming assay (SFA) 
Epithelial cells isolated from digested murine mammary glands or tumors were 
seeded under non adherent conditions in poly-HEMA-coated plates to generate 
spheres. The cells were seeded at a density of 50000 cells/ml for co-cultures in 
sphere medium (SM), with 10 ng/ml EGF, 10 ng/ml bFGF, 4 µg/ml heparin, 20 ng/ml 
hyper-IL-6, 5 ng/ml GRO-α and 1x B27 in basal medium. In experiments involving 
optimization or for studying the effect of conditioned medium on cells, the cells were 
seeded at a density of 10000 cells/ml. For control experiments only EGF, bFGF and 
heparin were added to the basal medium. The culture plates were incubated in a cell 
culture incubator at 37° C in atmosphere containing 5.5% CO2 and 7% O2.  
 
2.2.8. Preparation of poly-HEMA and low attachment plates 
To prepare coating solution, 2.4 g of poly-hydroxy-ethyl-methyl-acrylate (Poly-HEMA) 
were added to 20 ml of 95% ethanol and put on a shaker at 65° C to dissolve for ~8 
hours. To the above dissolved poly-HEMA, 80 ml of 95% ethanol was added and 
mixed. The prepared solution could be stored indefinitely at 4° C. Poly-HEMA solution 
was added to the cell culture dishes at a final density of 0.8 mg/cm (w/v). The plates 
were dried overnight in a sterile hood with lids slightly opened. The poly-HEMA-
coated plates can be stored indefinitely until use at +4° C. 
 
2.2.9. Methylcellulose preparation 
Medium with methylcellulose (MC) was prepared to culture bone marrow cells in 
vitro. Methocel was used as a thickening agent in sphere cultures to limit the lateral 
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movement and thereby aggregation of cells. A stock solution of 1% MC was prepared 
and diluted to 0.2% in sphere medium for culturing bone marrow cells. Briefly, 1 g of 
MC was added to 20 ml of boiling basal medium and mixed on a magnetic stirrer for 
2 hours at 95° C. Eighty ml of cold basal medium was added and allowed to dissolve 
overnight at 4° C on a magnetic stirrer. The medium was collected into an 
ultracentrifuge tube and centrifuged for 30 min at 7500xg to remove any undissolved 
MC. The medium was transferred into a 50 ml tube leaving the pellet at stored at 4° 
C. The medium with MC is stable for 4 weeks. 
 
2.2.10. General cell membrane labeling with PKH26 and CellVue® 
PKH26 (PKH) and CellVue (CV) are general cell membrane labeling dyes. PKH26 is 
visible under Cy3 and CV under Cy5 filter. Cells prepared from BM, MEC or cell lines 
were centrifuged at 400xg for 5 min in a 50 ml tube. The cells were washed once in 
1x PBS or serum free medium to remove any traces of serum. The supernatant was 
discarded and the cell pellet was resuspended in 1 ml Diluent C. Immediately, before 
staining 1 µl of PKH or 2 µl of CV were added to 999 µl or 998 µl of Diluent C solution 
respectively. The dye solution was added to the cell suspension, mixed gently and 
incubated for 5 min. The staining reaction was stopped by adding 2 ml of 20% BSA 
for 1 min and centrifuged at 400xg for 10 min. After discarding the supernatant, the 
pellet was resuspended in medium containing BSA, transferred to a new 50 ml tube 
and centrifuged for 10 min at 400xg. The cells were washed 3 times with BSA 
containing medium to remove unbound dye and counted on a Neubauer chamber. 
  
2.2.11. Co-culture 
Mammary epithelial cells (MEC) isolated from BALB/c or BALB-neuT were cultured 
with BALB-neuT bone marrow cells enriched for EHS (see 2.2.6). The mammary 
epithelial cells were stained with CellVue and EHS-fraction with PKH26 (see 2.2.10). 
The cells were seeded in a poly-HEMA-coated 6 cm dish in 5 ml sphere medium. 
MECs were seeded at a density of 50000 cells/ml together with 200000 cells/ml of 
EHS and incubated at 37° C, 5.5% CO2 and 7% O2. The cultures were replenished 
with fresh medium every week until they were terminated. 
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2.2.12. Transwell assay 
Transwell plates are cell culture dishes with a transwell insert. The insert has a 
microporous (0.4 µm) membrane which separates the dish in to upper (UC) and 
lower compartments (LC). The microporous membrane allows only soluble factors to 
pass through between the compartments (figure 4). In the UC 50000 cells/ml of 
MECs or 10000 cells/ml of cell lines were seeded. The cells in the UC were stained 
with PKH26. In the lower chamber 100000 cells/ml EHS cells were seeded in sphere 
medium containing 0.2% methylcellulose. The medium was changed once every 
week for the first two weeks and after the second week the medium was changed 
every third day. For screening or changing medium, the upper chamber was carefully 
removed and placed in a new petri dish with 5 ml basal medium. After screening or 
changing medium the upper chamber was carefully placed back in the transwell dish. 
This was done to avoid any spillage of cells in the upper chamber while transporting 
the plates to the microscope or while changing the medium in the upper chambers.  
 
Figure 4: Transwell assay experimental setup 
The transwell assay is divided into an upper and a lower compartment by a microporous 
membrane. Transwells can be used to study the effect of two different cell types on each 
other. The pore size of the membrane used for the experiments in this study is 0.4 µm which 
allows only soluble factors to pass through the membrane. The upper chamber contains 
primary mammary cells or cell lines stained with PKH26 and the lower chamber contains BM 
cells enriched for EHS. MEC: Mammary epithelial cells. 
 
2.2.13. Conditioned medium preparation 
After density centrifugation, 200000 cells/ml of bone marrow cells from BALB/c, 
BALB-neuT or NSG mice were seeded in basal medium supplemented with EGF (5 
ng/ml), bFGF (5 ng/ml), heparin (4 µg/ml) and B27. After 3 days the cultures were 
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collected in a 50 ml tube and centrifuged for 10 min at 1000xg to pellet the cells. The 
supernatant was sterile filtered through a 0.22 µm filter to remove any cells in the 
conditioned medium. The medium was used immediately or stored at -80° C until 
further use. 
 
2.3. Molecular methods 
2.3.1. Immunocytochemical staining: Her2 staining on adhesion slides 
Bone marrow (BM) cells on the adhesion slides were taken out of -20° C and thawed 
for 20 min. Blocking solution (5% mouse serum in 1x TBS) was added to the slides to 
rehydrate the cells and to block unspecific binding of antibodies to the cells. After 20 
min the blocking solution was discarded and primary antibody against Her2 (table 1) 
was added and incubated for 60 min. The primary antibody was discarded and the 
slides were washed 3 times for 3 min in 1x TBS. The slides were incubated with the 
secondary antibody (table 1) for 25 min and washed 3 times for 3 min each in 1x TBS 
followed by incubation with avidin-biotin complex (ABC) coupled with alkaline 
phosphatase (AB/AP system) for 25 min. Finally, the development system of the 
BCIP/NBT for alkaline phosphatase enzymatic substrate was added for 10 min. The 
slides were washed 3 times for 3 min and screened for Her2 positive cells. The 
positive cells were typically violet-to-black in color. TUBO, a tumor cell line derived 
from a murine primary mammary tumor of BALB-neuT which expresses Her2, was 
used as a positive control. For antibodies and concentrations used, please refer to 
table 1. 
 
2.3.2. Cytokeratin 8/18 staining on adhesion slides 
The procedure for CK8/18 staining of cells on adhesion slides is as explained in 
2.3.1, except for the antibodies (table 1). TUBO cells express CK8/18 and were used 
as a positive control. 
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Table 1:  List of antibodies used for immunocyto- and immunohisto chemical 
staining against CK8/18 and Her2. 
Antigen Against Conjugate Source Isotype Conc. Product code 
c-erbB-2 
(Her2-neu) 
Mouse,Rat, 
Human 
 
Rabbit IgG 5 µg/ml 29D8 
IgG Rabbit Biotin Goat IgG 5.5 µg/ml D-111-065-144 
Cytokeratin 
8/18 
Mouse,Rat, 
Human 
 
Guinea 
pig IgG 1:200 GP11 
IgG Guinea pig Biotin Goat IgG 1.6 µg/ml D-106-065-003 
 
2.3.3. Haematoxylin and eosin staining of paraffin embedded tumor tissue 
Paraffin embedded tumor tissue was cut into 5 µm sections onto a slide. The 
sections were deparfinized in Xylol for 10 min twice and rehydrated first in 100% 
ethanol for 3 min and then in 80% ethanol for 3 min. The sections were washed in 1x 
PBS for 1 min thrice and incubated with hematoxylin for 45 sec. The slides were 
rinsed in tap water for a short duration and washed in tap water for 30 min in a glass 
cuvette. Eosin (0.1%)was added to the tissue sections and after 2 min they were 
washed with ddH2O for 1 min. The stained sections were dehydrated in 70% ethanol 
for 2 min, 100% ethanol for 2 min and finally in xylol for 15 min. Mounting gel was 
added to the tissue sections and a cover slip was placed carefully on the gel avoiding 
bubbles and were left to dry overnight. 
 
2.3.4. Immunohistochemical staining of paraffin embedded tumor tissue 
Paraffin tissue sections were stained for CK 8/18 or Her2. Briefly, the paraffin slides 
were rehydrated as explained in 2.3.3. Antigen retrieval was performed by boiling the 
slides in microwave oven for 2 min and cooling for 2-3 min at RT and was repeated 5 
times. After the slides were washed 3 times in 1x PBS for 1 min, they were incubated 
in 3% H2O2 and methanol for 30 min at RT to neutralize endogenous peroxidase 
activity. After washing thrice in 1x PBS for 1 min, tissue sections were blocked with 
5% goat serum for 30 min. The sections were incubated with primary antibody (table 
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1) for 60 min and washed with 1x PBS 3 times for 1 min. After incubating with 
secondary Ab for 30 min, the slides were washed in 1x PBS once for 3 min and 
incubated with ABC-HRP for 30 min. The ABC-HRP was washed with 1x PBS 3 
times for 3 min, DAB development system was added and incubated for 5 min. The 
slides were first washed 3 times in PBS, once in ddH2O for 2 min and counter-stained 
with haematoxylin for 3 mins. Haematoxylin was discarded and washed for 2 min first 
with ddH2O, then with tap water and again with ddH2O. The slides were dehydrated 
gradually in 80% and 100% ethanol for 3 min each and in xylol for 10 mins. Mounting 
gel was added to the slides and was left overnight to dry. 
 
2.3.5. Isolation and amplification of mRNA from single spheres 
The mammospheres from NMEC and TMEC cultures were picked with a 2 µl pipette 
tip in 1 µl volume of the medium using a microscope. For co-cultures, single PKH 
positive spheres were picked. The isolated spheres were added to a 4 µl lysis buffer 
with 0.4 µl tRNA and stored at -20° C.  
Isolation and amplification of mRNA was performed as published. (Hartmann and 
Klein 2006). 
 
2.3.6. Preparation of genomic DNA along with mRNA 
Using Ampl1™ kit from Silicon Biosystems, genomic DNA was prepared from the 
supernatants collected during mRNA isolation from single cells. 
 
2.3.7. PCR 
To identify samples carrying the rat Her2 transgene, PCRs were performed on the 
genomic DNA isolated from spheres, tumor cells or cell lines. Transgene specific 
primers were added to the PCR reaction mixture along with the DNA to amplify the 
rat Her2 transgene. 
The contents of the PCR reaction were as follows: 
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Primers used for amplification of Her2 transgene were: 
 
 
2.3.8.  Array CGH data analysis 
The array-CGH (aCGH) was performed on Agilent microarrays and the data was 
analyzed using Agilent Workbench 6.5®.  The aberration algorithm used was ADM-2. 
 
2.3.8.1. Labeling of sample DNA (preparation for array CGH procedure) 
Test and reference DNA were labeled with SureTag DNA Labeling Kit (Agilent) 
according to the manufacturer’s instructions. Briefly, 1.5 - 2.0 µg of purified input 
DNA (WGA product of unamplified genomic DNA) was supplemented with 5 µl of 
Random Primer Mix and filled up with H2O to 31 µl. Samples were denatured at 95
◦C 
for 10 or 3 min in the case of unamplified DNA and WGA products, respectively. 
Sample tubes were transferred to ice and incubated for 5 min. The labeling reaction 
with exo-Klenow fragment consisted of: 31 µl of denatured template DNA, 10 µl of 5x 
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reaction buffer, 5.0 µl of 10x dNTP mix, 3.0 µl of Cy5-dUTP (test) or Cy3-dUTP 
(reference) and 1.0 µl of Exo(-) Klenow fragment. For all the experiments gender-
matched test and reference samples were used. The labeling reaction was run at 37◦ 
C for two hours followed by inactivation at 65◦C for 10 min.  
 
Labeled DNA was purified using Ultra 0.5 purification system (30 kDa – cut-off). 
Briefly, DNA samples were supplemented with water to a total volume of 480 µl and 
applied on the purification column. Samples were centrifuged for 10 min at 14000xg. 
Following removal of the flow-through 480 µl of H2O was applied on the column and 
samples were centrifuged again (10 min, 14000xg). Spin columns were removed 
from the spin column assembly, inverted and placed in fresh collection tube. DNA 
was collected by centrifugation for 1 min at 1000xg at room temperature. The 
quantity of purified DNA was assessed using Nano Drop ND-1000 instrument.  
 
2.3.8.2. Array comparative genomic hybridization 
Array CGH was performed on oligonucleotide-based SurePrint G3 Mouse CGH  
4x180K microarray slides (design code: 027411) according to the protocol provided 
by the manufacturer (Agilent Technologies) with slight modifications. Hybridization 
mix was comprised of 5.0 µg of Mouse Cot1-DNA (Invitrogen), 11 µl of 10x Blocking 
Reagent (Agilent Technologies) and 55 µl of 2x Hi RPM hybridization buffer. The 
hybridization mix was mixed with 19 µl of test and reference DNA and applied on the 
array. Hybridization was carried out at 65° C for 24 h after which, they were washed 
twice for 2:30 min in Oligo aCGH/ChIP-on-Chip wash buffer 1 at room temperature, 
twice for 30 sec in Oligo aCGH/ChIP-on-Chip Wash Buffer 2 at 37◦ C. Washed slides 
were immersed in acetonitrile to remove all remaining traces of the wash buffers  and 
were later scanned using an Agilent Microarray Scanner Type C. 
 
2.3.8.3. Processing and analysis of the aCGH data 
Microarray TIFF files were processed and quantified with the Agilent Genomic 
Feature Extraction Software (version 10.7). The resulting SHP files were imported 
and analyzed with Agilent Genomic Workbench Software (version 6.5 Lite or 7.0). 
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Aberrant regions were recognized using ADM-2 algorithm with a threshold set to 6.5. 
To avoid detection of false positive aberration calls, aberration filters were applied to 
define the minimum log2 ratio (0.2 and 0.3 for unamplified DNA and WGA products, 
respectively) and the minimum number of probes in the aberrant interval (5 and 10 
for unamplified DNA and WGA products, respectively). 
 
2.3.8.4. Cluster analysis 
Cluster analysis was performed using Euclidean distance based on the aCGH data of 
the cell lines. This clustering feature was provided in the Workbench 6.5® by Agilent. 
 
2.3.9. Genomic DNA preparation 
The genomic DNA was isolated using Qiagen QIAmp DNA mini kit according to the 
manufacturer’s instructions. 
Materials: 
Antibodies 
Reagents Manufacturer 
29D8 (anti-Neu/-HER-2)  Cell signaling 
BA-9500 (anti-goat-IgG; Biotin)  Vector Laboratories 
D-106-065-003 (anti-goat-IgG; Biotin)  Dianova 
D-106-165-003 (anti-goat-IgG; Cy3)  Dianova 
D-111-065-144 (anti-rabbit-IgG; Biotin)  Dianova 
DLN-12082 (anti-c-erbB-2/-HER-2/-neu)  Dianova 
G8.8-Bio (anti-EpCAM; Biotin)  Biolegend 
GP11 (anti-cytokeratin 8/18)  Progen 
Microbeads (anti-IgG2a+b) Miltenyi Biotech 
Microbeads (anti-biotin) Miltenyi Biotech 
Microbeads (anti-FITC) Miltenyi Biotech 
Sca-1- (anti-mouse Sca-1:FITC) Miltenyi Biotech 
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Buffers and solutions 
Solutions Composition 
20x SSC (Saline–Sodium Citrate)  0,3 M sodium citrate 
  3 M NaCl 
  70 % ethanol  
  70 ml 100% ethanol 
  30 ml water 
  85 % ethanol l  
  85 ml 100% ethanol 
  15 ml Water 
Hematoxylin 2 g haematoxylin 
  0,4 g sodium iodate 
  100 g aluminium potassium sulfate 
  100 g chloralhydrate 
  2 g citric acid 
Differentiative epitthelial medium RPMI medium without L-glutamine 
  10 % FCS 
  200 U/mL penicillin 
  200 U/mL streptomycin 
  2 mM L-glutamine 
PBS (Phosphate Buffer saline)  8,5 mM Na2HPO4 
  2 mM KH2PO4 NaCl 
  150 mM NaCl 
  pH 7,4 
PCR-buffer + dNTPs  100 mM Tris-HCl 
  500 mM KCl 
  10 mM MgCl2 
  1 mM of each nucleotide 
TBE-buffer, pH 8,3  89 mM TRIS 
  89 mM boric acid 
  2 mM EDTANa2 
TE-Puffer, pH 7,4  10 mM TRIS-HCl 
  1 mM EDTA 
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Cell culture media 
Solutions Composition Final conc 
Basal medium 500 ml DMEM/F12   
  5 ml HEPES buffer  100 nM 
  5 mlPen/Strep  1x 
  BSA 0.5% 
  500 µl Insulin  5 µg/ml 
Sphere medium (primary culture) 48.8 ml basal medium   
  1 ml B27 1x 
  50 µl EGF  10 ng/ml 
  50 µl heparin  4 µg/ml 
  20 µl bFGF  10 ng/ml 
  25 µl GRO-α  5 ng/ml 
  10 µl HIL-6  20 ng/ml 
Sphere medium (BM transwell) 38.8 ml basal medium   
  10 ml 1% metthylcellulose 0.2% 
  1 ml B27  1x 
  50 µl EGF  10 ng/ml 
  50 µl heparin  4 µg/ml 
  20 µl bFGF  10 ng/ml 
  25 µl GRO-α  5 ng/ml 
  10 µl HIL-6  20 ng/ml 
Sphere medium (cell lines) 48.8 ml basal medium   
  1 ml B27  1x 
  50 µl EGF  10 ng/ml 
  50 µl heparin  4 µg/ml 
  20 µl bFGF  10 ng/ml 
TUBO medium to 500 ml DMEM   
  100 ml FCS  20% 
  5 ml 2mM L-glutamine  1x 
C3HT101/2 medium to 500 ml DMEM   
  25 ml FCS  5% 
  5 ml 2mM L-glutamine  1x 
DCC cell line medium 500 ml RPMI 1640   
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  50 ml FCS  10% 
  5 ml 2mM L-glutamine  1x 
  5 ml Pen/Strep  1x 
Cell lines 
Consumables 
Product Manufacturer Catalog# 
Adhesion slides Roth   H8701 
Filter (0.22 μm) Roth   P666.1 
Syringe needles (26G) Braun  C7181 
Cell culture plates Schubert and Weiss, OMNILAB FALC351007 
Cell culture flasks Sarsted 831.810.302 
Glass slides Langenbrinc 03-0001 
6 well plates Greine 657160 
Reaction tubes 1,5 ml  CLN Gmb CLN-BÖT1.5 
Reaction tubes 0,2 ml Abgen AB-0337 
Transwell plates (10 cm) Cornin 3419 
Enzyme, growth factors and Development system 
Product Manufacturer Catalog # 
2-Log DNA-Ladder 1kb  NEB N32005 
AB/AP-System  DAKO AK-5000 
AB/HRP-System  DAKO PK-4000 
Material Origin 
TUBO Cell line from BALB-neuT primary tumor. 
C3HT101/2 
mouse embryonic fibroblasts (received from Prof. John 
Stingl, Cambridge University, Cambridge, UK) 
Immortalised fibroblast 
mouse fibroblasts (received from Prof. Robert Weinberg, 
Whitehead Institute, MA, USA ) 
NIH3T3 mouse embryonic fibroblasts 
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AB-Serum  Bio-Rad  805315 
Agarose  Sigma-Aldrich  A3038 
B27  Invitrogen 17504-44 
BCIP/NBT  BioRad 1706432 
bFGF  Sigma-Aldrich F0291 
BSA  Roche  1071145001 
CellVue® Sigma-Aldrich,  MINICLATER-1KT 
Collagenase Type I CellSystems biotech LS4196 
DAB  DAKO K3468 
DEPC-H2O  Invitrogen   750023 
Diluent C Sigma-Aldrich CGDIL-6x10 ml 
Dispase Invitrogen D4818 
DMEM  Pan-Biotech P04-03500 
DMEM/F12  Pan-Biotech P04-41500 
EGF Sigma-Aldrich E9644 
Eosin  Sigma-Aldrich 54802 
Ethanol absolute  J.T. Baker 8006 
Ethidium bromide (1 %)  Sigma-Aldrich E8751 
Eukitt (Mounting gel)  Sigma-Aldrich 03989-100ML  
Expand Long Template 
Enzyme Mix Roche 11 759 060 001 
FCS  PAN Biotech P30-3702  
Goat serum DAKO X0907 
GRO-α RnDsystems 275GR 
Hematoxylin Sigma-Aldrich MHS16 
Heparin Sigma-Aldrich H3149 
Hyaluronidase Type IV-S Sigma-Aldrich H4272 
Igepal  Sigma-Aldrich I3021-50ML 
Insulin Sigma-Aldrich I9278 
Isopropanol  Fluka 59300-2.5ML 
Levamasol Sigma-Aldrich L9756 
L-Glutamin (200 mM)  Pan-Biotech P04-80100 
Matrigel  BD Biosciences 356231 
Methanol  VW 1.06009.2500  
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Methyl cellulose Sigma-Aldrich M0512-100G 
Mouse serum  DAKO X0910 
Mse I 50 U/μl  New England Biolabs R0525M 
OPA Plus  Amersham Biosciences,  27-0901-02 
Panscript Taq-
Polymerase  PAN Biotec MB-30010250 
Paraformaldehyde VW 104005  
Penicillin/Streptomycin 
(10 U/μL)  Pan-Biotech P1-010 
Percolll  Amersham Biosciences 17089102 
PKH26  Sigma-Aldrich MINI26-1KT 
Polyhema  Sigma-Aldrich P3932 
Proteinase K  Roche 03115828001 
RPMI 1640  Pan-Biotech P05-17500 
Sodium citrate  Sigma-Aldrich 73894-100ML 
T4 DNA Ligase  Roche 10799009001 
Tween 20  Sigma-Aldrich P9416 
Xylol  Roth 9713.3 
 
Equipment 
Instrument Manufacturer 
Cell culture incubator Heraeus  
Flourescence microscope Leica  
Heat block thermo mixer 5436,  Eppendorf 
Inverted microscope Leica  
Refrigerated centrifuge Eppendorf  
Micromanipulator Microinjector 5242,  Eppendorf 
MJResearch  Peltier Thermal Cycler PTC-
200 Bio-Rad 
Voltmeter EPS 200,  Pharmacia Biotech 
UV-screen  INTAS 
Video camera  INTAS 
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Water bath Memmert 
Centrifuge  Eppendorf  
Cytospin centrifuge Hettich  
Dissection tools for mouse Heiland 
Kits 
Kits used Manufacturer 
Ampli 1™ Silicon Biosystems 
PKH26 general cell membrane labeling Sigma-Aldrich 
CelVue general cell membrane 
labeling Sigma-Aldrich 
QIAmp DNA mini kit Qiagen 
SureTag DNA Labeling Kit Agilent technologies 
SurePrint G3 Mouse CGH  4x180K 
microarray slides Agilent technologies 
Oligonucleotides and Primers 
All oligonucleotides and primers were manufactured by Metabion, Munich. 
Primer Sequence 
ddMse11   TAA CTG ACA G-ddC 
Her2 AT 5’  CAG ATT GTC TCA CCA GGT G 
Her2 AT 3’  CTC ATT GCT ATT CCA AAT GCC 
Her2 GG 5’  GAG ACG CTC AAC CTC AA TTG 
Her2 GG 3’  GGC ACT TGT TGG TCT GTA G 
LIB1  AGT GGG ATT CCT GCT GTC AGT 
Transgene 5’ (MTV) GTA ACA CAG GCA GAT GTA GG 
Transgene 3’ (BRL) ATC GGT GAT GTC GGC GAT AT 
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Software 
Product Manufacturer 
Axiovision Ver.4.8 Carl-Zeiss GmbH 
Graphpad®  Graphpad software Inc. 
Agilent Workbench 6.5 Agilent technologies 
 
 
List of Abbreviations 
In this work, internationally accepted chemical symbols and abbreviations of SI units 
(Système International d`Unités) were used.  
Ab Anti body 
bp  Base pair 
BCIP  
5-Bromo-4-chloroindol-3-ol dihydrogen 
phosphate ester mono-p-toluidinium salt 
BM Bone marrow 
BM-Tr Bone marrow of transplanted mouse 
BSA  Bovine serum albumin 
bFGF Basic fibroblast growth factor 
cDNA  Complementary deoxyribonucleic acid 
aCGH  Array comparative genomic hybridization 
CM Conditioned medium 
CK  Cytokeratin 
CSC Cancer stem cell 
DCC Disseminated cancer cell 
ddH2O  Deionized distilled water 
DNA  Deoxyribonucleic acid 
DMSO Dimethyl sulphoxide 
EGF Epidermal growth factor 
EpCAM Epithelial cell adhesion molecule 
EHS EpCAM, Her2 and Sca-1 enriched 
FCS  Fetal calf serum 
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FITC  Fluorescein isothiocyanate 
GRO-α Growth related oncogene-alpha 
HE  Haematoxylin-Eosin 
ICC  Immunocytochemistry 
IgG  Immunoglobulin G  
IHC  Immunohistochemistry 
HIL-6 Hyper-interleukin-6 
MEC Mammary epithelial cells 
MMTV  Mouse-mammary tumor virus 
MRD  Minimal residual disease 
NBM  Normal bone marrow 
NMEC Normal mammary epithelial cells 
NSG 
NOD scid IL2 receptor gamma chain 
knockout mouse 
NSG BM NSG mouse bone marrow 
PBS  Phosphate buffer saline 
PCR  Polymerase chain reaction 
PFA  Para-formaldehyde 
RKI  Robert Koch Institute 
RT  Room temperature 
Sca-1 Stem cell antigen-1 
SDF-1 Stromal derived factor-1 
SM  Sphere medium 
StM Standard medium 
SV40 Simian Virus 40 
TBM  Tumor bone marrow  
TBS  Tris buffer saline 
TMEC Tumor mammary epithelial cells 
TW Transwell 
UV  Ultra violet 
WT, wt Wild type 
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3. Results 
The main aim of this study was to establish 1) in vitro culture conditions to propagate 
and expand bone marrow derived disseminated cancer cells (DCC) and 2) to 
establish in vitro DCC cell line model to study DCCs. 
 
3.1. Prostate bone marrow DCC and tumor cell culture 
The first aim of my doctoral thesis was to identify and establish conditions to culture 
DCCs in vitro. I first tested the standard conditions, used in sphere culture to 
generate prostatospheres from tumor cells of prostate cancer patients. Single cells 
were isolated from the tumor tissues and seeded in basal medium (see materials 
buffers and solutions) supplemented with EGF, bFGF and B27 at a density of 10000 
cells/ml.  Cultures were observed for spheres after 7 days and spheres with a 
diameter of 50 µm and above were counted (figure 5). An average of 60 
prostatospheres was counted in the sphere cultures. These conditions were then 
used to culture DCCs from the bone marrow (BM) of prostate cancer patients. DCCs 
from the BM of prostate cancer patients cultured in sphere conditions did not 
generate any spheres. We then cultured the patient BM in adherent conditions to see 
whether attachment could initiate growth in the DCCs. The cultures were screened 
for adherent colonies but this condition also failed to initiate growth in DCCs (table 2). 
Although, in bone marrow 3D cultures there were some sphere-like structures they 
never grew beyond 20 µm even after 4 weeks in culture.  
 
Figure 5: Bone marrow and prostate tissue of patients in culture. 
A) Prostatosphere from single cells isolated from prostate tumor tissue of prostate cancer 
patients post surgery. 10000 cells/ml were seeded and cultured for 7 days and spheres > 50 
µm were counted and B) sphere-like structure in the prostate cancer patient bone marrow 
cultures prostate cancer patients. The BM cells were cultured for 4 weeks at a density of 
200000 cells/ml. Although sphere-like structures appeared in the BM cultures they never 
exceeded 20 µm. 
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Table 2: Bone marrow and tumor tissue of prostate cancer patients in culture. 
Sample type No. of samples Condition Spheres/Colonies 
Prostate tumor tissue 2 3D 60 (55+65) 
Prostate BM 5 3D 0 
Prostate BM 9 2D 0 
3D cultures were screened for spheres and 2D cultures were screened for adherent colonies. 
2D: adherent and 3D: non adherent or suspension cultures. 
 
When the patient bone marrow was cultured the positivity of the sample for the DCCs 
or the number of DCCs in the positive samples was not known. So, in order to know 
the number of DCCs that went in to culture, patient BM was stained with EpCAM 
(epithelial cell adhesion molecule) or CK8/18 (cytokeratin 8 and 18) epithelial 
markers to identify the DCCs (table 3). 
Table 3: EpCAM and CK8/18 status of patient BM samples. 
Sample Id Condition EpCAM (per 10
6
) CK 8/18 (per 10
6
) 
PC-272 2D n.a Negative 
PC-277 2D Negative n.a 
PC-280 2D n.a Negative 
PC-284 2D n.a Negative 
PC-298 2D n.a 1 
PC-316 2D n.a 3 
PC-324 2D n.a Negative 
PC-325 2D n.a Negative 
PC-326 2D Negative Negative 
PC-816 3D 2 1 
PC-826 3D 5  Negative  
PC-831 3D 2 Negative 
PC-838 3D 4 Negative 
PC-901 3D 6 n.a 
n.a=not assessed. 2D: adherent and 3D: non adherent or suspension cultures. 
3.2. Identifying in vitro DCC culture conditions using BALB-neuT breast 
cancer mouse model 
Patient bone marrow samples were highly variable with respect to the number of 
samples positive for DCCs and the number of DCCs per positive sample (table 3). 
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Moreover, there is variability between prostate cancer patients also   . Thus, we used 
the BALB-neuT breast cancer mouse model. In BALB-neuT mice DCCs can be 
detected in bone marrow (BM) by cytokeratin 8/18 (CK8/18) staining from week 4 at a 
frequency of 1-10 per 5x105 BM cells. The Workflow of the experiments involving 
BALB-neuT BM DCC culture is shown below in figure 6.   
 
Figure 6: Workflow of the project. 
Mammosphere assay was first established using mammary epithelial cells isolated from the 
mammary glands of normal or tumor tissue and was later optimized. The optimized 
conditions were then applied to the BM cells enriched for EpCAM, Her2 and Sca-1 from 
tumor bearing mice to culture DCCs in vitro. Since the DCCs failed to grow in mammosphere 
conditions the possible suppressive effect of BM cells on mammary cells was tested in 
coculture or monoculture. Eventually, the supportive effect of mammary epithelial cells was 
also tested in both mono- and coculture experiments. Spheres formed in coculture 
experiments were later characterized molecularly and functionally and then expanded in vitro 
to generate cell lines. 
 
3.2.1. Establishing protocol for generating mammospheres 
Formation of spheres from mammary epithelial cells (MEC) isolated from mammary 
glands of both normal (BALB/c, wild type) and transgenic (BALB-neuT) mice was first 
tested to establish a working protocol for generating mammospheres. Epithelial cells 
isolated from mammary glands of either BALB/c or BALB-neuT were cultured under 
non adherent conditions to generate spheres as mentioned in materials and methods 
(2.2.3). The cells were seeded standard sphere medium (StM) (see Materials for 
buffers and solutions) supplemented with growth factors EGF, bFGF, which are the 
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standard growth factors used for sphere culture, along with B27 supplement, a serum 
replacement used for the survival of cells under non adherent conditions (Liao, 
Zhang et al. 2007). The cells were cultured at a density of 10000 per ml for 7-10 days 
and subsequently spheres with a diameter of 50 µm and above were counted (figure 
7). These basic conditions were subsequently modified. 
 
Figure 7: Sphere forming assay. 
Mammospheres from mammary epithelial cells isolated from A. BALB/c and B. BALB-neuT. 
Spheres 50 µm in diameter or above were counted. Number of cells seeded for 
mammosphere generation was 10000 cells/ml in standard growth factors; EGF, bFGF along 
with B27 supplement, a serum replacement used in suspension cultures.  
 
3.2.2. Increase in the cell density increases sphere number but not the 
frequency of sphere forming cells 
To examine if increase in cell density increases the frequency of sphere forming 
epithelial cells, normal or tumor MEC was seeded at different cell densities. Cells 
were seeded at 10000, 25000, 50000 and 100000 cells/ml in 5 ml of StM, and 
spheres were counted after one week. The frequency of sphere forming cells per 
1000 cells was higher at 25000 cells/ml for TMEC and 10000 cells/ml for NMEC 
(figure 8 A). The frequency of sphere forming cells decreased with the increase in cell 
density for both NMEC and TMEC. The reduction in the frequency of sphere forming 
cells was mainly due to the aggregation of cells at higher densities. As seen in figure 
8B, with the increase in density the number of clusters also increased especially in 
TMEC sphere cultures. The cell clusters were more prominent at 100000 cells/ml 
(figure 8C). The number of clusters was highest at a density of 100000 cells/ml which 
may have resulted in the decrease of both the frequency of sphere forming cells and 
the number of spheres. The TMEC compared to NMEC produced more than twice 
the number of spheres in culture. These results indicate that cell density in cultures 
A B 
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does affect the frequency of sphere forming cells. For experiments optimizing 
different conditions, cells at a density of 10000 cells/ml was used for both NMEC and 
TMEC. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Optimizing cell density for sphere culture. 
NMEC and TMEC cells were seeded in different densities to identify the optimal condition for 
sphere generation with the standard growth factors EGF and bFGF, (A) Sphere forming 
efficiency of NMEC and TMEC at different cell densities, (B) Spheres and clusters in TMEC 
cultures at different cell densities and (C) sphere and cluster in TMEC cultures at a density 
of 100000 cells/ml. NMEC: normal mammary epithelial cells, TMEC; tumor mammary 
epithelial cells. 
 
3.2.3. Effect of hyper Interleukin-6 (HIL-6) on mammosphere formation 
The standard sphere culture conditions containing growth factors EGF and bFGF did 
not yield any success in generating DCC spheres even in prostate bone marrow 
where DCCs were detected (3.1). Therefore, cytokines known to have a mitogenic 
effect on cells were tested in addition to EGF and bFGF. Two different cytokines 
were first tested on MECs to optimize conditions for sphere culture assuming that 
these conditions would trigger growth in BM DCCs. 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine known to play a role in cell 
proliferation. IL-6 signals through its membrane bound specific receptor, IL-6r, and 
A B 
C 
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two surface bound gp130 molecules.  Hyper IL-6 (HIL-6) is a fusion protein, where IL-
6 is fused to its soluble receptor (sIL-6r). This molecule does not require its specific 
membrane bound IL-6 receptor and signals through gp130 alone. Since all cells 
express gp130 it is advantageous to use HIL-6 as even non IL-6 responsive cells 
(cells lacking IL-6r) respond to HIL-6. To assess the effects on mammosphere 
formation different concentrations of HIL-6 were tested, from 1 ng to 50 ng. The 
number of spheres increased with the increase in HIL-6 concentration from 1 ng to 20 
ng but decreased at 50 ng (figure 9 A). However, the decrease in the sphere number 
at 50 ng was not due to fusion of spheres. Although the average sphere diameter 
increased from 1 to 50 ng (figure 9 B) the highest number of spheres could be 
observed at a concentration of 20 ng. For further mammosphere experiments, we 
therefore used HIL-6 at an end concentration of 20 ng/ml. 
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Figure 9: Effect of HIL-6 at different concentrations on mammosphere 
generation. 
10000 cells/ml were seeded in a 6 well plate in 5 ml. After seven days in culture pictures of 
every sphere was taken using Axiovison software under the microscope and spheres >50 µm 
were counted after measuring the diameter of every single sphere. (A) total number of 
spheres was counted and (B) average diameter of spheres was also calculated by 
measuring the diameter of every sphere in culture. The experiment was performed in 
triplicates. 
 
3.2.4. GRO-α and HIL-6 on mammospheres generation 
Another cytokine GRO-α, growth related oncogene α, also known as melanoma 
growth stimulatory activity (MGSA) alpha belongs to CXCL1 family of chemokines. 
GRO-α is known to have a potent mitogenic effect on the neighboring cells especially 
on premalignant epithelial cells (Coppe, Patil et al.) Since DCCs are epithelial derived 
cells I found it apt to test GRO-α first on mammary epithelial cells. To observe the 
effects of GRO-α alone or in combination with HIL-6, GRO-α was added to normal 
A B 
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and tumor mammary epithelial cells in sphere medium supplemented with and 
without HIL-6. 10000 cells/ml were seeded and cultured for 7-10 days thereafter the 
number of spheres was counted. As shown in figure 10, the number of spheres in 
cultures treated with either HIL-6 or GRO-α increased compared to the control 
medium containing only EGF and bFGF. Among the different conditions tested (figure 
10 A), the number of spheres in cultures with either HIL-6 or GRO-α was similar 
indicating that GRO-α has an equal potential ability to induce proliferation in cells as 
HIL-6 (figure 10 B). In conditions where both GRO-α and HIL-6 were present the 
number of spheres increased. Although the number of spheres generated by the 
tumor cells was higher the effect of both cytokines on both the normal and tumor 
(figure 10) mammospheres was similar. Based on these results the sphere medium 
with HIL-6 (20 ng/ml) and GRO-α (5 ng/ml) in addition to EGF and bFGF was found 
optimal and was used for future sphere cultures. This medium hereafter will be 
referred to as sphere medium (SM) and the medium with EGF and bFGF only will be 
called standard medium (StM) 
 
        
 
Figure 10: Effect of cytokines on the mammosphere forming efficiency of MEC.  
(A) Sphere forming efficiency of normal (NMEC) and tumor mammary epithelial cells (TMEC) 
isolated from murine mammary glands. Different cytokines were added to the sphere 
medium and their effect on the mammosphere generation was observed and (B) overview of 
p values from t-test performed comparing different conditions. E: EGF, F: bFGF, H: HIL-6, G: 
GRO-α. The cells were seeded at a density of 10000 cells/ml 5 ml of medium. Spheres >50 
µm were counted after 7 days in culture. The experiment was performed in triplicates. *n.a = 
not applicable. 
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 3.3. Mammary epithelial cells but not the freshly isolated fibroblasts 
generate spheres 
The epithelial cell isolation from mammary glands is based on the principle of 
differential centrifugation where the epithelial cells are isolated centrifuging at 200xg 
for 3 min and fibroblasts at 350xg for 4 min. Although these two cell types are 
isolated at different centrifugal speeds the possibility of fibroblast contamination in the 
epithelial fraction could not be ruled out. Therefore, the sphere forming ability of the 
fibroblasts under non adherent conditions was tested.  
In the first experiment we checked the sphere forming ability of established murine 
fibroblast cell lines (NIH3T3, C3HT101/2 and Immortalized fibroblasts) in SM. All 
tested cell lines were able to form spheres under mammosphere conditions, figure 11 
A and B.  The C3HT101/2 spheres although spherical were not compact as the 
epithelial cell derived mammospheres. On the other hand, the immortalized fibroblast 
cells formed compact spheres similar in appearance to mammospheres. NIH3T3 
cells did grow in suspension but looked more like cell aggregates, loosely bound, not 
compact and without a clear outer periphery typical for epithelial cell derived 
mammospheres. Surprisingly, the fibroblast cell lines generated more spheres 
compared to NMEC (~8 fold) or TMEC (~5 fold) (figure 11) at the same cell density 
(10000 cells/ml). 
 
 
 
 
A 
B 
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Figure 11: Sphere assay of fibroblast cell lines. 
(A) Fibroblast cell line spheres under mammosphere conditions with EGF, bFGF, GRO-α, 
HIL-6 and (B) number of spheres generated by each fibroblast cell line with a seeding 
density of 10000 cells/ml. The experiment was performed in triplicates and repeated twice. 
 
Since these cell lines have been in culture for long periods of time they could have 
acquired growth capabilities differing from primary cells. Therefore, we asked, if 
freshly isolated fibroblasts from murine mammary tissue also possess the ability to 
survive in suspension and form spheres.  
Mammary epithelial and fibroblast cells were isolated by differential centrifugation 
from both BALB/c and BALB-neuT mammary tissue. Since primary fibroblasts were 
never tested for their ability to form spheres, they were seeded at 50000 cells/ml to 
exclude low cell density as one of the factors leading to the failure of fibroblasts to 
form spheres in SM. After 7 days the fibroblast cultures were screened for spheres 
and compared to spheres from epithelial cultures. The mammary epithelial cells 
formed spheres in non adherent conditions in SM, but fibroblasts neither from BALB/c 
nor BALB-neuT could form spheres under identical conditions (figure 12 A and B). 
These results indicate that albeit the fibroblast cell lines have sphere forming ability, 
freshly isolated mammary fibroblasts lack the capability to survive in suspension 
cultures and form spheres. 
 
 
 
 
 
Figure 12: Comparison of sphere forming ability of mammary epithelial and 
fibroblast cells. 
(A) freshly isolated mammary fibroblasts and epithelial cells from murine mammary glands 
were cultured in sphere medium; (B) spheres > 50 µm and above were counted after 7 days 
in culture for NMEC, TMEC and their respective fibroblasts. All experiments were done in 
triplicates and repeated twice. Seeding density was 50000 cells/ml.  
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3.4. In vitro propagation of murine bone marrow derived DCC 
To test if SM can induce proliferation in DCCs, BM DCCs were cultured in the SM. 
Bone marrow from BALB-neuT (TBM) and normal BALB/c (NBM) were collected and 
mono nucleated cells were isolated by 60% percoll gradient (P60) centrifugation. BM 
cells were either cultured directly or further enriched for EpCAM, Her2 (EH) or 
EpCAM, Her2 and Sca-1 (EHS) and cultured in sphere medium. As shown in table 4, 
none of the bone marrow samples cultured, P60, EH or EHS could form spheres.  
Table 4: BM cells cultured in different conditions to propagate DCC in vitro. 
      
 
 
 
 
 
 
 
 
 
 
 
 
             
EH: EpCAM, Her2; EHS: EpCAM, Her2, Sca-1; DCCD: DCC density. 
The BM samples, enriched and non-enriched were stained with CK8/18 to confirm 
the presence of DCCs. Although, both non-enriched and EH or EHS enriched BM 
were positive for CK8/18 (figure 13) they did not grow in sphere conditions. 
Furthermore, the DCC density (DCCD) in the BM when stained with CK8/18 
increased after enrichment (table 6) with 125 CK+ cells in EHS, 60 CK+ in EH and 7 
in non enriched BM. There were a few small sphere-like structures in cultures with 
EHS enriched cells but these never grew in size and were below 20 µm in diameter. 
There were many clusters with loosely bound cells in non-enriched BM cultures but 
nothing that could be defined as spheres. Interestingly, these loosely bound cell 
clusters reduced with EHS enrichment. 
Bone marrow  Enrichment Depletion Medium Spheres Colonies 
BALB/c No No SM No - 
BALB-neuT No No SM No - 
BALB/c EH No SM No - 
BALB-neuT EH No SM No - 
BALB/c EHS No SM No - 
BALB-neuT EHS No SM No - 
BALB/c EHS No RPMI+FCS - No 
BALB-neuT EHS No RPMI+FCS - No 
BALB/c - EHS RPMI+FCS - No 
BALB-neuT - EHS RPMI+FCS - No 
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Figure 13. CK8/18 staining of bone marrow before and after enrichment. 
BM of BALB-neuT was stained for CK8/18 after percoll 60 (P60), EpCAM and Her2 
enrichment (EH) and EpCAM, Her2 and Sca-1 (EHS) enrichment for the presence for 
disseminated cancer cells on adhesion slides. TUBO expresses CK8/18 and was used as 
the positive control. Ø 1° Ab: without primary antibody. 
Fetal calf serum (FCS) contains many factors which support the growth of cells in 
vitro and is routinely used in cell culture. To see if serum could trigger growth in 
DCCs in normal cell culture conditions, EHS cells were isolated from 3 mice each for 
BALB/c and BALB-neuT were cultured separately on 3 regular cell culture dishes in 
RPMI with 10% FCS and observed for the formation of any adherent colonies.  As 
indicated in table 5, addition of FCS failed to initiate DCC growth. These results imply 
that the mammosphere condition was not efficient in triggering growth of the bone 
marrow DCC nor was the normal cell culture. Nevertheless, the density of DCCs 
(DCCD) after enrichment with EpCAM, Her2 and Sca-1 increased (table 5). 
Therefore for further cultures EHS enriched BM was used.  
Table 5: DCCD in enriched and un-enriched BM. 
Bone marrow Enrichment DCCD 
BALB/c No 0 
BALB/c EH 0 
BALB/c EHS 0 
BALB-neuT No 7 
BALB-neuT EH 60 
BALB-neuT EHS 125 
EH: EpCAM, Her2; EHS: EpCAM, Her2, Sca-1; DCCD: DCC density. 
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3.5. Effect of bone marrow cells on the sphere forming efficiency of 
epithelial cells 
 
3.5.1 Coculture of bone marrow cells with TMECs 
We hypothesized that the bone marrow only supports for the survival of DCC but 
exerts a growth suppressive effect. To test this hypothesis TMECs were co-cultured 
with bone marrow cells of transgenic mice (TBM). Additionally, to see if in the 
absence of DCCs the effect of BM cells on TMECs would be any different from TBM 
with DCCs, TBM was depleted of EpCAM, Her2 and Sca-1 (TBM w/o EHS) and co-
cultured with TMECs. NSG mice are deficient in mature T cells, B cells and natural 
killer cells (NK) and are defective in several cytokine pathways (Shultz, Schweitzer et 
al. 1995; Shultz, Lyons et al. 2005). To observe if NSG also has a suppressive effect 
TMECs were cocultured with NSG bone marrow cells (NSG-BM). TMECs were 
stained with PKH26, a cell membrane labeling dye, to differentiate from the BM cells 
in co-cultures. After seven days in culture the number of PKH26 stained spheres 
were counted as shown in figure 14 A. In the presence of TBM cells the number of 
mammospheres decreased compared to the number of mammospheres in TMEC 
monoculture, figure 14 B. TMEC mammospheres further decreased when cultured 
with EHS depleted TBM cells. The reduction of TMEC spheres in NSG-BM was 
significant (t-test p=0.0257) suggesting some effect of NSG-BM cells on TMEC. 
However, compared to NSG-BM the effect of TBM on TMEC (t-test p<0.001) was 
highly significant and the effect of TBM depleted of EpCAM, Her2 and Sca-1 on 
TMEC (t-test p<0.0001) was even more significant. There were no spheres in the BM 
monoculture controls. These results suggest that the BM cells could exert a 
suppressive effect on tumor cells.  
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Figure 14: The effect of BM cells on TMEC and their ability to form spheres. 
Spheres stained with PKH26 and with a diameter of 50 µm or above were counted. 50000 
cells/ml of TMEC and 200000 cells/ml of BM cells were seeded in cocultures. (A) Spheres 
from TMEC cultured in different culture conditions, (B) number of spheres from TMEC in 
different culture conditions were counted and culturing for 7 days. Statistical analysis was 
performed using unpaired t-test; *p>0.05; ***p<0.001; ****p<0.0001. TBM Ø EHS/TBM-EHS: 
EpCAM, Her2 and Sca-1 depleted. Experiment was repeated thrice in triplicates. 
 
A 
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3.5.2 Effect of BM conditioned medium on sphere forming ability of TMECs 
We hypothesized that factors secreted by bone marrow cells may play a role in 
suppressing DCC growth in the bone marrow. Therefore, conditioned media (CM) 
from bone marrow of tumor mice (TBM) and bone marrow of NSG mice (NSG-BM) 
were prepared by culturing the cells in non adherent conditions for 3 days with EGF 
and bFGF. The medium was collected and filtered through a 0.22 µm filter to remove 
cells. Later TMECs were seeded at a density of 50000 cells/ml and cultured in their 
respective CM supplemented with EGF, bFGF, GRO-α and HIL-6. Mammospheres 
formed in both the CM with reduced frequency (figure 15 A). The reduction in NSG-
BM compared to SM (t-test p<0.0001) and TBM compared to NSG-BM CM (t-test 
p<0.001) were significant. To test the effect of BM conditioned medium in the 
absence of GRO-α and HIL-6 and later if GRO-α and HIL-6 can overcome the effect 
of CM, TMECs were seeded in CM without GRO-α and HIL-6 and compared to CM 
supplemented with GRO-α and HIL-6. In addition, the epithelial cell density was 
decreased to 10000 cells/ml for ease of counting spheres and to exclude high cell 
density as one of the factors for high sphere numbers as seen in the previous 
experiment (figure 15 A). As controls TMECs were seeded in standard sphere 
medium with or without GRO-α and HIL-6. The medium was always supplemented 
with EGF and bFGF for all conditions. Spheres > 50 µm were counted after one week 
in culture. The number of spheres in the NSG-BM CM without GRO-α and HIL-6 
compared to normal medium (DMEM/F12) without GRO-α and HIL-6, reduced 
significantly (figure 15 B and C). The effect of conditioned medium from TBM on 
TMECs was even more significant when compared to NSG-BM CM with a further 
decrease in sphere numbers. Addition of GRO-α and HIL-6 did not increase the 
sphere forming efficiency of TMEC cells in TBM CM. The number of TMEC spheres 
in TBM CM decreased with respect to NSG-BM CM with GRO-α and HIL-6. This 
effect was also highly significant (figure 15 C).These results indicate that BM 
conditioned medium of BALB-neuT does have a suppressive effect on the tumor cells 
Is this suppression an innate property of the BM or is it due to the presence of 
primary tumor or DCCs in the bone marrow? To test if the suppressive effect of the 
BM is a consequence of the primary tumor or DCCs present in the BM, TMECs were 
grown in NBM CM to check if NBM CM also suppressed the growth of TMEC. 
Interestingly, TMEC in NBM CM also generated less spheres either in the presence 
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or absence of GRO-α and HIL-6 compared to TMEC spheres in their respective 
NSG-BM conditioned media cultures. This reduction in sphere numbers was also 
highly significant (figure 15 B and C). Based on these results it can be concluded that 
the BM exerts a suppressive effect on TMECs and supplementing the conditioned 
media with GRO-α and HIL-6 could not abrogate this effect.  
 
 
 
 
Figure 15. Suppressive effect of BM CM on TMEC. 
(A) number of spheres in the BM conditioned media from BALB-neuT (TBM) NSG (NSG-BM) 
mice, cell density 50000 per ml; (B) comparison of spheres between TBM ,NSG-BM and 
BALB/c BM (NBM) conditioned medium to with and without GRO-α and HIL-6 and (C) 
overview of p-values from unpaired t-test performed to examine the effect of different CM on 
TMECs. Cell were seeded at 10000 cells/ml. Experiment was performed thrice in triplicates 
and spheres > 50 µm were counted. EGF and bFGF are standard growth factors in the 
sphere medium and GRO-α and HIL-6  are added in addition these factors. CM: conditioned 
medium, NBM: BALB/c bone marrow, NSG-BM: NSG mouse bone marrow, TBM: BALB-
neuT bone marrow and n.a: not applicable. 
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3.6.  Effect of mammary epithelial cells on bone marrow DCCs 
 
3.6.1.  Mammary epithelial cells induce proliferation in bone marrow DCCs 
Tumor cells secrete many factors and some of these have a growth promoting effect 
on their neighboring cells (Celis, Gromov et al. 2004). We sought to see if these 
tumor cells or their secreted factors have any effect on the DCCs in the bone marrow. 
Bone marrow from the BALB-neuT was isolated, enriched for EHS and cocultured 
with TMECs to observe for their effect on BM DCCs. To differentiate between the two 
cell populations the BM cells were stained with PKH26, a general cell membrane 
labeling dye. After 1 week spheres > 50 µm stained with PKH26 were counted in the 
cocultures with TMECs (figure 16 A and B) indicating that the TMECs do induce 
growth in the DCCs in the bone marrow. EHS cells from BALB-neuT were also 
cultured with NMECs to see if the growth inducing effect on DCCs was an exclusive 
property of the TMECs. In the presence of NMECs the DCCs were also able to form 
spheres suggesting that the growth inducing effect was not a property confined to 
TMECs (figure 16 A and C). As a control, NMEC was cocultured with NBM to 
examine if NMECs can activate cells in the normal BM other than DCCs. The number 
of PKH26+ spheres in the co-cultures was high and was comparable to their 
respective MEC controls. We assume that many of the spheres contained a mixture 
of DCCs and MECs making it difficult to distinguish between DCC only and 
DCC+MEC derived spheres. As controls, NBM and NMECs from three different 
BALB/c mice were isolated and co-cultured in SM. The NBM cells were stained with 
PKH26 to distinguish them from NMEC. NMEC did not have any effect on the NBM 
cells confirming that the growth inducing effect is selectively on the DCCs.  
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Figure 16: Propagation of DCCs through coculture of TBM with TMECs and 
NMECs. 
(A) Spheres from coculture experiment, NMEC and TMEC spheres, DCC spheres in TBM 
stained with PKH26 visible under Cy3 channel and unstained spheres originating either from 
A 
B C 
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NMEC or TMEC in the coculture and TBM spheres in monoculture and (B) graph showing 
TBM DCC spheres with tumor mammary epithelial cells (TMEC) as cocultures and (C) graph 
showing TBM DCC spheres cocultured with normal mammary epithelial cells (NMEC). 
PKH26 stained spheres > 50 µm were counted. The results are from 3 independent 
experiments of TMEC cocultures and 2 independent experiments of NMEC cocultures. 
***p<0.001, ****p<0.0001. 
 
3.6.2.  PCR to confirm the identity of TBM spheres 
To confirm the identity of the BM spheres in the cocultures, PKH26+ spheres from 
the cocultures were picked and checked for the presence of Her2 transgene through 
PCR. As controls spheres from NMEC and TMEC were picked and a PCR was 
performed for the transgene. TMECs carry the rat Her2 oncogene but not NMECs 
(figure 17 A). The resultant PCR product for rat Her2 oncogene is 220 bp.  As 
expected all the spheres picked from TBM+TMEC co-cultures carried the transgene 
serving as a positive control (figure 17 B). Importantly, the PKH26+ spheres picked 
from NMEC+TBM co-cultures carried the Her2 transgene confirming the origin of the 
spheres. 
          
           
Figure 17: Transgene PCR to confirm the identity of PKH26+ spheres.  
(A) PCR for Her2 transgene on PKH26 positive (PKH+) spheres picked from NMEC and 
TMEC cocultures and (B) PCR for Her2 transgene on spheres picked from NMEC and TMEC 
monoculture controls. NMEC do not carry the transgene hence NMEC mammospheres are 
negative for the rat Her2 PCR. PCR band for Her2 transgene is 220 bp and for wild type is 
180 bp. 
  
The PKH26+ spheres could expand in vitro as cell lines and were tumorigenic when 
injected sub cutaneously into NSG mice (table 6). It was surprising to note that the 
A 
180 bp 
B 
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cell lines lacked the Her2 transgene. Furthermore, neither the tumor cells nor the cell 
lines expressed CK8/18 or Her2. Therefore, the identity of the cell lines or the tumors 
could not be determined as they were neither epithelial nor DCC derived.  
 
Table 6: Characterization of the cell lines and tumors derived from PKH26+ 
spheres. 
Experiment Spheres Cell lines Tumor 
Transgene 
in cell lines 
CK8/18 and 
Her2 staining 
TMEC + TBM PKH26+ yes 2/2 absent Negative 
TMEC + TBM PKH26- yes 2/2 absent Negative 
 
3.7. Effect of tumor cell secreted factors on TMECs 
Do cell secreted factors also play a role in activating DCCs? To investigate the role of 
secreted factors in eliciting DCC growth in vitro, a transwell assay was setup. In 
addition, the transwell separated the two cell populations thereby preventing 
contamination by either population. 
For this assay, a metastatic mouse mode, a modification of the BALB-neuT model 
was used (Husemann, Geigl et al. 2008). Briefly, pre-malignant mammary gland of a 
4 week old BALB-neuT mouse is transplanted in a 4 week old BALB/c mouse. The 
cells from the transplanted tissue after malignant transformation disseminate to the 
bone marrow of the recipient BALB/c mouse. The advantage of this mouse model is 
that only the DCC in the BM carry the transgene while in BALB-neuT all the cells 
carry the rat Her2 transgene. Hence, this mouse model provided a better and cleaner 
background in identifying DCCs. 
 
3.7.1 Transwell assay to test the effect of secreted factors on BM DCCs 
Bone marrow from 5 transplanted mice were pooled and later enriched for EHS. 4 
mice of the 6 pooled had metastasis. The EHS enriched BM of transplanted mice 
(EHS-BMTr) was seeded in the lower chamber and NMEC or TMEC were seeded in 
the upper chamber. The EHS-BMTr was also cocultured with TUBO, an established 
primary tumor cell line from BALB-neuT, and C3HT101/2, a murine embryonic 
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fibroblast cell line, to see if these cell lines would also influence DCC proliferation. As 
an additional measure to identify contamination in the BM compartment of the 
transwell plates, the MECs and cell lines were stained with PKH26 (figure 18 A). As a 
control one transwell plate only with PKH26+ cells in the upper chamber was added 
and treated similarly as the rest of the transwell plates. The cells were cultured for 4 
weeks with medium change at regular intervals (2.2.11). After four weeks spheres 
negative for PKH26 and > 50 µm could be observed in the BM compartment, figure 
18 B. Spheres from BM formed only in transwells where TMEC and TUBO cells were 
the stimulators. Neither NMEC nor C3HT101/2 cell line could stimulate the BM DCCs 
to proliferate. Although, NMECs induced growth in DCCs in the coculture assay they 
failed to induce any growth in DCC in the transwell assay (figure 18 B). After 
quantifying the BM spheres transwell cultures, the upper chamber with TMEC or 
TUBO was removed and the BM was further cultured for 4 weeks. This was done to 
examine if the activated DCCs required continuous stimulation for being in an active 
state. Interestingly, by week 8 the number of spheres in the BM cultures even after 
the removal of the stimulators increased (figure 18 C). As controls the normal bone 
marrow was cultured in the presence of NMEC and TMEC, which were earlier shown 
to have a positive effect on the DCC proliferation in TBM, in the coculture assay 
(3.5.1). NBM cells did not form any spheres. Neither TMEC nor NMEC had any 
influence on normal BM cells and neither of them could induce sphere formation in 
NBM. The results indicate that tumor cell secreted factors play a role in activating the 
BM DCCs. 
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Figure 18: Transwell assay to propagate DCC from the bone marrow of 
transplanted mice. 
Cell lines and MECs were stained with PKH26 and seeded in the upper chamber. The MECs 
were seeded at 50000 cells/ml and cell lines at 10000 cells/ml. BM from 6 transplanted mice 
were pooled, enriched for EHS and seeded at 100000 cells/ml in the lower chamber of the 
transwell plate.(A) Spheres from different transwell conditions tested. TMEC and TUBO are 
stained with PKH26 to identify any contamination in the BM chamber. (B) number of spheres 
C 
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formed in different culture conditions with the upper chamber until week 4 and thereafter 
without the upper chamber until week 8. LC: lower chamber 
 
3.7.2 Cytokeratin 8 and 18 staining of the transplanted bone marrow 
To determine the number of DCCs present in the BM of transplanted mice (BM-Tr), 
adhesion slides of the BM-Tr were prepared to stain for cytokeratin 8 and 18 
(CK8/18). The CK 8/18 staining was positive for the transplanted bone marrow, figure 
19. About 175 cells per 1*106 BM cells were stained positive for CK8/18 (table 6). 
 
Figure 19: Cytokeratin 8/18 staining of BM-Tr.  
Adhesion slides prepared from the BM of transplanted mice were stained for CK 8/18. TUBO 
cell line was used as a positive control for CK staining along. CK positive cells are dark 
purple colored cells. 
 
3.7.3. EpCAM, Her2 and Sca-1 cells from the bone marrow have the ability to 
form spheres in a transwell assay 
So far, the BM was enriched for all the three markers, EpCAM, Her2 and Sca-1, 
making it difficult to determine the population of cells that contained sphere forming 
DCCs. To identify the cell population with sphere forming DCCs, the bone marrow of 
eight transplanted mice were pooled, split into three parts and enriched for EpCAM, 
Her2 or Sca-1 as shown in figure 20 A. Two of the 8 pooled mice had metastasis. 
Since, TUBO was shown to induce growth in DCC; the enriched cells were cultured 
in transwells in the presence of TUBO. After 3 weeks, spheres appeared all the three 
cell populations (EpCAM, Her2 and Sca-1) in transwells cultured with TUBO. EpCAM 
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had the highest number of spheres and Sca-1 the least. TUBO failed to induce any 
growth in the EpCAM, Her2 or Sca-1 enriched cells of NBM in transwells (figure 20 
B). After counting the spheres, the upper chamber was removed and the BM cells 
were cultured further. The spheres in all three cell fractions increased in number by 
week 6. There was a three-fold increase of spheres in Sca-1 and around two-fold for 
EpCAM. In Her2, the increase in sphere number was around 1.4 fold. These results 
indicate that both EpCAM and Sca-1 had a higher frequency of proliferating DCCs 
than Her2. 
 
 
 
Figure 20: Sample preparation and transwell assay. 
(A) Schematic representation of BM enrichment from transplanted mice and culture and, (B) 
number of spheres from the BM in the lower chamber of the transwell in week three and in 
week six. After week three the upper chamber was removed and the lower chamber with BM 
was cultured further until week six. Spheres with a diameter of 50 µm and above were 
counted. 
A 
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3.7.4. CK 8/18 staining of the BM-Tr of EpCAM, Her2 and Sca-1 fractions 
To determine the number of DCCs in the BM enriched for EpCAM, Her2 or Sca-1, 
adhesion slides from the enriched fractions prepared before transwell culture were 
stained for CK 8/18 (figure 21). The number of CK 8/18 positive cells in EpCAM and 
Her2 BM fractions was similar while in Sca-1 the number of CK positive cells was far 
less (table 6). Surprisingly, the number of spheres in the Her2 fraction did not 
increase much though cells positive for CK in Her2 was high (table 7).  
 
Figure 21: CK 8/18 staining of EpCAM, Her2 and Sca-1 fractions of BM-Tr. 
Adhesion slides or cytospins from the bone marrow of EpCAM or Her2 or Sca-1 enriched 
fraction were stained for Her2 or CK to indentify the number of DCCs in their respective 
fractions. CK positive cells are stained dark purple in color. TUBO was used as control. Ø 1° 
Ab; without primary antibody, BM-Tr: bone marrow of transplanted mice. 
 
Table 7: Number of CK positive cells counted for different BMTr fractions per 
106 bone marrow cells on adhesion slides. 
    No. of spheres/CK8/18 cells 
BM sample DCCD Spheres Week 3 Spheres week 6  Week 3 Week 6  
BM-Tr (EHS) 175 99 199 0,57 1,14 
BM-Tr EpCAM 260 70 178 0,27 0,68 
BM-Tr Her2 267 60 83 0,22 0,31 
BM-Tr Sca-1 80 20 57 0,25 0,71 
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3.7.5. PCR to confirm the identity of spheres from the BM of transplanted 
mice 
To confirm the presence of transgene and thereby the origin of sphere forming cells, 
genomic DNA of BM spheres picked from 3.6.1 and 3.6.3 were examined for the 
presence of Her2 transgene. As shown in the figure 22, all the spheres picked 
transwell experiments carried the transgene. These results imply that the spheres 
from BM-Tr were derived from activated DCC and the factors secreted by TMEC and 
TUBO can selectively activate bone marrow DCCs. 
 
    
Figure 22: Transgene PCR on the isolated DNA of spheres from different 
transwell conditions. 
Gel (A) shows the presence of rat Her2 transgene in the spheres picked at 220 bp and the 
gel (B) shows PCR bands for the WT Her2 (control) at 180 bp. 1:   BM-Tr  Her2, 2:   BM-Tr 
EpCAM,  3:   BM-Tr Sca-1, from 3.6.2 transwell experiment and, 4:   TMEC+BM-Tr (EHS) 
and  5: TUBO+BM-Tr (EHS) from 3.6.1 transwell experiment. P: Positive, N: Negative and L: 
Ladder.  
 
3.8. In vivo tumorigenicity of spheres generated from the transwell 
assays 
The ability to proliferate in vitro does not imply that the DCCs posses the capability to 
initiate tumors. Therefore, the tumorigenicity of DCC spheres from the transwells was 
tested in vivo. BM spheres from the transwells (table 8) were picked and transplanted 
orthotopically into BALB/c or sub-cutaneously into NSG mice.  
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Table 8: In vivo transplantation of spheres generated in different transwell 
conditions. 
Mouse id Condition No of DCC spheres Injection site Tumor 
 Feeder Cells Test Cells    
3940 (BALB/c) TUBO EHS 50 Mammary fat pad Yes 
3941 (BALB/c) TUBO EpCAM 50 Mammary fat pad Yes 
3942 (BALB/c) TUBO Her2 50 Mammary fat pad Yes 
3943 (BALB/c) TUBO Sca-1 32 Mammary fat pad Yes 
4072 (BALB/c) TMEC EHS 40 Mammary fat pad Yes 
90-17 (NSG) TMEC EHS 50 Sub cutaneous Yes 
 
All the mice transplanted with DCC spheres developed tumors implying that some 
cells within the spheres displayed tumor initiating potential. The tumors were 
removed and a small part of the tumor was cryo-preserved and another part was 
paraffin embedded. Rest of the tumor was digested to prepare single cells (see 
3.8.2). The paraffin embedded tumor tissue sections were stained with haematoxylin 
and eosin and all tumors appeared to be epithelial in origin (figure 23).  
 
Figure 23: H & E staining of paraffin embedded sections. 
Paraffin sections of tumors derived from transwell sphere transplants in the mammary fat pad 
of BALB/c mice. 3940, 3941, 3942 and 3943 are the mouse numbers of the respective 
transwell sphere transplants. 
 
3.9. Generation of DCC cell lines 
The second aim of my project was to generate cell line from DCCs which can later be 
used to study these cells. Primary cell culture is very challenging especially in 
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culturing and generating cell lines from a particular cell type (Epithelial or fibroblast). 
Fibroblasts could sometimes grow faster and outgrow epithelial cells when cultured 
together or when epithelial cultures are contaminated with fibroblasts. Tumor tissue 
consists of both epithelial and fibroblast cells. Thus, to generate epithelial cell 
cultures isolated from tumor tissue it is important to eliminate fibroblast contamination 
from these cultures.  
 
3.9.1. Establishing a method to generate cell lines in vitro from mammary 
epithelial cells of BALB-neuT mouse 
Although the freshly isolated fibroblasts did not survive in non-adherent, serum-free 
conditions, contaminating fibroblasts could survive in the presence of serum. The 
possibility of the fibroblasts outgrowing epithelial cells also could not be completely 
ignored. Therefore, a method was first established to eliminate or at least minimize 
fibroblast contamination and generate an epithelial cell line from BALB-neuT primary 
tumors. Therefore, two procedures 1) low centrifugation speed (200xg) for isolating 
epithelial cells from digested mammary tissue and 2) serum free medium, in which 
fibroblasts cannot survive were used. MECs were isolated from an 18 week old 
BALB-neuT mouse (BnT18) and 10000 cells per cm2 were seeded in 2 different 
conditions, DMEM+20%FCS which is used to culture TUBO cell line and 
RPMI+10%FCS commonly used to culture epithelial cell lines. The cells were seeded 
in a T-25 flask and incubated at 37° C, 5.5% CO2 and 7% O2. After 24 hours of 
plating the cells, the medium was removed and replaced with StM (basal 
medium+EGF+bFGF+heparin+B27) and incubated for 24 hours. The cells were later 
trypsinized and centrifuged at 200xg for 3 min to pellet epithelial cells and re-plated in 
their respective serum containing medium. This was repeated 3 times and later the 
cells were checked morphologically under the microscope for any stromal cell 
contamination in the culture flasks (figure 24 A). The cells seeded in DMEM+20% 
FCS were very few and did not survive to generate a cell line however; the cells in 
RPMI+10% FCS were able to grow into a cell line (figure 24 B) and looked epithelial 
in morphology as short compact colonies of cells. The cells were also stained with 
epithelial markers CK8/18 and Her2 and compared to TUBO cell line used as a 
positive control to confirm the epithelial identity of the cell line (figure 24 C). Based on 
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these results RPMI+10%FCS was used to generate cell lines from tumors generated 
by transwell spheres in vivo. 
 
 
 
Figure 24: Generating cell line from MEC of BALB-neuT mouse in vitro. 
(A) Workflow of the procedure for in vitro cell line generation. (B) phase contrast pictures of 
MECs seeded in DMEM+20% FCS or RPMI+10% FCS after each treatment, shown as a box 
A 
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in the workflow. (C) Adhesion slides prepared from BnT18 cell line cultured in RPMI+10% 
FCS with 500000 cells per slide were stained for CK8/18 and Her2. TUBO cell line used as a 
positive control for CK8/18 dn Her2. BnT18; cell line generated from MECS of an 18 week 
old BALB-neuT mouse, Ø 1° Ab: without primary antibody. 
3.9.2. Generation of cell lines from tumors derived from transplanted DCC 
spheres 
To answer the question if the cells from DCC initiated tumors could expand in normal 
cell culture conditions, single cells prepared from the tumors were seeded in RPMI 
medium supplemented with 10% FCS in a normal cell culture flask at a cell density of 
10, 000 cell/cm2. The medium was changed the next day to remove non adherent or 
dead cells as explained in the methods section. The culture flasks were treated as 
explained in the previous section. Tumor cells isolated from all the tumors seeded to 
generate cell lines were able to grow and expand in vitro in a week. The primary cell 
lines could be maintained and propagated in vitro for several passages (figure 25). 
The cells in the cell culture flasks looked epithelial growing together as small colonies 
representing cobblestone morphology. 
 
Figure 25: In vitro expansion of activated DCC. 
Cell lines generated from the tumor cells of tumors originated from transwell spheres. The 
single cells were generated from tumors grown in BALB/c mice transplanted with transwell 
spheres. 10000 cells/cm2 were seeded in RPMI + 10% FCS in a cell culture flask and treated 
as explained in 3.8.1. 
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3.10. Staining tumors and cells derived from in vivo transplanted spheres 
Paraffin embedded tumor tissues from transwell spheres transplanted into BALB/c 
mice and cells isolated from these tumors were stained with CK8/18 and Her2 to 
confirm that they were of epithelial and DCC origin. 
 
3.10.1. Immunohistochemical staining of paraffin embedded tumors with 
CK8/18 and Her2 
From paraffin embedded tumors (section 3.7) 5 µm thick sections were prepared. 
The tumor sections were stained for CK 8/18 and Her2 to confirm if the tumors were 
epithelial and originated from the DCC derived spheres. As a control, primary tumor 
from BALB-neuT was also stained for CK 8/18 and Her2. All the tumors from the 
transwell spheres expressed CK8/18 and Her2 (figure 26).  
 
  
 
 
 
Figure 26: Immunohisto-chemical staining with CK8/18 and Her2. 
Paraffin embedded tumor tissue sections were prepared from tumors formed by transplanting 
spheres from different transwell conditions in the mammary fat pad of BALB/c mice. The 
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tumor tissues were stained for CK8/18 and Her2. Primary tumor of BALB-neuT was used as 
a control. 
 
3.10.2. CK8/18 and Her2 staining of tumor cells and cell lines on adhesion 
slides 
Adhesion slides were prepared from tumor cells and cell lines established from these 
tumor cells and stained for CK8/18 and Her2 to see if the cells expressed cytokeratin 
and Her2 and confirm their epithelial origin. Cells from all the tumors (figure 27 A) 
and cell lines (figure 27 B) were positive for CK8/18 and Her2. TUBO cells were used 
as control for both the staining.  
Figure 27: Immunocytochemical staining of tumor cell lines. 
Adhesion slides with 500000 cells per slide were prepared from tumor cells isolated from 
DCC induced tumor and cell lines established from the isolated tumor cells. The slides were 
stained for CK8/18 and Her2. (A) Cytokeratin 8/18 and Her2 staining of tumor cells and (B) 
CK8/18 and Her2 staining of tumor cell lines. TUBO was used as a positive control for 
CK8/18 and Her2. EHS: EpCAM, Her2 and Sca-1. 
 
A 
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3.11. Her2 transgene PCR of tumor cell and DCC cell lines 
Additionally, a PCR was performed on the DCC derived tumor cells and DCC cell 
lines generated from these tumor cells to look for the presence of the rat Her2 
transgene and confirm their DCC origin. All the cells from tumors and the cell lines 
carried the transgene (figure 28 A) again confirming their DCC origin. A PCR for the 
WT Her2 was also performed as a control (figure 28 B), lower panel. Together the 
results from CK8/18, Her2 staining along with Her2 transgene PCR suggests the 
tumors and the cell lines are DCC derived. 
 
 
Figure 28: Transgene PCR on genomic DNA isolated from tumor cells and the 
cells from the cell lines generated from the tumors. 
Genomic DNA was isolated from tumor cells and cell lines established from transwell 
spheres and checked for the presence of Her2 transgene. PCR was performed for rat Her2 
oncogene and the corresponding PCR bands were observed on 1.5% agarose gel after gel 
electrophoresis. Upper gel (A) shows Her2 transgene at 220 bp while the lower gel (B) 
shows bands for WT Her2 at 180 bp. 2D = cell lines. 
 
3.12. Genomic aberration of cell lines by array comparative genomic 
hybridization 
Tumor cells are known to exhibit an aberrant genomic profile with deletions and 
amplifications across their genome. An aCGH was performed on cell lines generated 
from the tumors of transplanted transwell DCC spheres along with TUBO to see if 
they were genomically aberrant and compared to TUBO. TUBO carried least number 
A 
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of aberrations, mostly deletions, and 4072 was highly aberrant with aberrations 
across all chromosomes and mostly amplifications (figure 29 A and B). However, 
deletion on chromome 4 was shared by all the cell lines while deletion on 
chromosome 14 was shared only between TUBO, 3940, 3941, 3942 and 3943.  
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Fig 29: aCGH profile of DCC cell lines. 
Tumor from the mice generated by the DCC sphere transplants were digested and isolated 
cell single cells were grown as adherent cultures to generate DCC cell lines. gDNA was 
isolated from the DCC lines and an aCGH was performed to obtain a genomic profile of the 
cell lines. (A) An aCGH profile of TUBO compared to DCC cell lines. Cell lines 3940, 3941, 
3942 and 3943 were derived from tumors generated by spheres grown in the presence of 
TUBO. DCC cell lines 4072 and 90-17 were derived from tumors generated by spheres 
grown in the presence of TMECs and (B) an overview of genomic aberrations of all the cell 
lines. Red: Amplification, Green: Deletion 
 
3.13. Cluster analysis of all the cell lines based on the aCGH data 
The DCC cell lines were heterogeneous in their genomic profile and shared a few 
aberrations with TUBO. To see how similar the cell lines are to each other and to 
TUBO, a cluster analysis was performed applying Euclidean distance using the 
aCGH data of all the cell lines. As shown in figure 30, cell lines 4072 and 90-17 from 
the same experiment but were shown to be similar to each other. Although the 
spheres were injected in different mice and at different sites (table 6) they were 
clustered together. On the other hand 3940 and 3943 were similar to each other and 
B 
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were also placed closer to TUBO suggesting these two cell lines (3940 and 3943) are 
more similar to TUBO than rest. 3941 and 3942 were placed away from the rest of 
the cell lines in two separate clusters implying that were different from the other cell 
lines. The DCC cell lines, 90-17 and 4072, derived from spheres grown in the 
presence of TMECs were closer to each other and also to TUBO. DCC cell lines 
3941 and 3942 were clustered separately from each other and also from TUBO.  
 
Figure 30: Euclidean distance or Manhattan clustering of the cell lines using 
the aCGH data. 
The cell lines were clustered using the aCGH data of the cell lines using Euclidean distance. 
The distance between two clusters is calculated as the arithmetic mean of distances between 
all possible pairs from the two clusters. The clustering has two major groups, one with 3942 
and the second with the rest of the cell lines. The difference between the groups is equal to 
length of the line joining them at the nearest node. 
 
3.14. DCCs from BALB-neuT also form spheres in the presence of TMECs in a 
transwell setup 
The DCCs cultured so far in a transwell setup were isolated from the BM of 
transplanted mice. Some of these mice in the both the transwell experiments had 
metastasis representing an M1 state of breast cancer. To examine if DCCs from 
BALB-neuT BM representing M0 stage disease can also propagate, BM of an 8 week 
old BALB-neuT mouse isolated enriched for EHS and cultured in the presence of 
TMECs isolated from the same mouse. The BM cells were stained with PKH26 and 
TMECs with CellVue, another unspecific cell membrane labeling dye which is visible 
under cy5 filter. The BM cells were seeded in the lower chamber and TMECs in the 
upper chamber (materials and methods 2.2.11). The transwell was observed every 
week for spheres. After 3 weeks spheres appeared in the BM chamber and spheres 
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>50 µm in diameter were counted (figure 31 A and B) and later the transwell with 
TMEC was removed and further cultured for another 3 weeks. The number of 
spheres from week 3 to week 5 an almost increase by 2 folds, similar to the 
observations made in earlier transwell experiments. The spheres were picked and 
whole transcriptome amplification and genome DNA isolation was performed. The 
genomic DNA carried the rat Her2 oncogene (figure 31 C) and expressed epithelial 
markers CK8/18 and EpCAM (figure 31 D) confirming their epithelial origin. The 
spheres were injected in to mice to test their tumorigenic ability, but unfortunately the 
mouse died of lymphoma and in vivo tumorigenicity of these in vitro activated DCCs 
could not be evaluated. However, an aCGH performed on one of the spheres 
showed an aberrant genomic profile but completely different to TUBO and the DCC 
cell lines (figure 31 E). Nevertheless, the aberrant genomic profile of the sphere may 
suggest that the sphere contained tumor cells. 
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Figure 31. Transwell coculture of TBM of 8 week old mouse with TMEC. 
Bone marrow from an 8 week old mouse was isolated, enriched for EHS and cocultured with 
TMEC isolated from the same mouse in a transwell. The EHS cells were stained with PHK26 
and the TMECs with CV to differentiate both the cell types. Spheres with a diameter of 50 µm 
or above were counted. (A) BM spheres stained with PKH26 (PKH) and TMEC spheres 
stained with CellVue, (B) number of spheres counted on week 3 in the presence of TMECs 
and on week 5 after removing upper chamber containing TMECs  (C) Her2 transgene in the 
genomic DNA (gDNA) of all the DCC spheres checked, (D) EpCAM and CK on cDNA 
libraries prepared from the DCC spheres. cDNA libraries and gDNA were prepared from the 
same spheres. (E) Array CGH profile of the DCC sphere 7 (from the PCR gel bands). 
E
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4.  Discussion. 
The main aim of this study was to 1) identify conditions suitable to propagate 
disseminated cancer cells (DCC) in vitro and 2) later expand them and generate cell 
lines. Limitations in studying DCC are that they are rare and there are no suitable 
markers to identify them. A major shortcoming in the progress of understanding these 
cells is the absence of a suitable in vitro model, a DCC cell line. It has been a 
challenge over the years to propagate these cells in vitro. 
Prostate BM samples cultured in both adherent and non adherent conditions failed to 
proliferate although prostate tumor epithelial cells did generate spheres in similar 
conditions. Identifying optimal conditions for propagating patient derived bone 
marrow DCC was always challenging. Various factors such as amount of bone 
marrow available, sample positivity for DCC and number of DCCs present per 
sample including patient variability (M0 or M1 stage or gleason score) could influence 
the outcome of the results. For example, if the BM in culture does not produce any 
spheres, it could be because of 1) the absence of DCCs in the BM sample in culture, 
2) the low number of DCCs in the sample in culture or 3) the culture conditions 
applied to propagate DCCs were not optimal. There were too many variables to 
consider. Thus, we examined DCCs in BALB-neuT, an established mouse model for 
breast cancer, to identify conditions suitable to propagate them in vitro. Studies in our 
group have shown that these mice contain DCCs in the bone marrow and can be 
detected by CK8/18 staining of the bone marrow cells from week 4 (Husemann, Geigl 
et al. 2008). Therefore, we found this mouse model suitable for isolating and 
establishing conditions for propagating DCCs and later expanding them in vitro.  
 
4.1. Mammosphere assay and bone marrow culture 
4.1.1. Mammosphere assay 
DCCs are rare in the bone marrow, 1-10 per million BM cells (Husemann, Geigl et al. 
2008 (Husemann, Geigl et al. 2008). Low DCC numbers per mouse limited us from 
testing different culture conditions on these cells initially. Furthermore, conditions to 
grow DCCs in vitro are not known. Thus, we first tried to optimize culture conditions 
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on murine mammary epithelial cells as spheres and later applied these conditions to 
culture DCCs in vitro. Studies have shown that non adherent serum-free cultures 
enrich for stem/progenitor cells (Dontu, Abdallah et al. 2003) and importantly it has 
been shown that fibroblasts cannot grow in serum-free non-adherent conditions 
(Kulkarni and McCulloch 1994). Furthermore, recent studies have shown that both 
DCCs and CTCs contain a population of cells expressing markers thought to be 
associated with stem/progenitor cells like CD44, ALDH in CTCs (Theodoropoulos, 
Polioudaki et al. 2010) and CD44, CD326 (EpCAM) and  ALDH in DCCs (Reuben, 
Lee et al. 2011). Hence, the BM cells were grown in serum-free non-adherent 
conditions as spheres to prevent differentiation induced by serum and adherent 
conditions (Bertolero, Kaighn et al. 1986; Masui, Wakefield et al. 1986) and preserve 
the stem/progenitor cells. Mammary tissue digestion, epithelial cell isolation and 
mammosphere culture conditions methods were adapted and modified from 
previously published work (Liao, Zhang et al. 2007; Eirew, Stingl et al. 2008). While 
both the groups (Liao et al. and Eirew et al.) used FCS in their cultures, serum was 
omitted to avoid differentiation of DCCs. Conditions were first optimized to culture 
mammospheres from both BALB/c and BALB-neuT mammary epithelial cells in vitro. 
The optimized sphere medium contained cytokines HIL-6 (hyper interleukin-6) and 
GRO-α (growth related oncogene-α) in addition to EGF and bFGF. Addition of these 
two cytokines increased the sphere forming efficiency of mammary epithelial cells. IL-
6 is a pro-inflammatory pleiotrophic cytokine which acts through its IL-6 receptor and 
two gp130 molecules activating JAK/STAT pathway and thereby promotes 
proliferation. Very few cells express IL-6r but all cells express gp130. HIL-6 is a 
fusion protein where IL-6 is fused to its soluble IL-6 receptor forming an IL-6/sIL-6r 
complex. This fusion protein can bind to gp130 and initiate gp130 mediated signaling 
cascade, called trans-signaling. Therefore, non responsive cells which lack IL-6 
receptor also respond to HIL-6 as they express gp130 (Fischer, Goldschmitt et al. 
1997; Rose-John, Waetzig et al. 2007). IL-6 was shown to play a role in inducing 
proliferation and is also involved in several inflammatory diseases and oncogenesis 
in breast cancers (Sansone, Storci et al. 2007), colon (Becker, Fantini et al. 2005), 
and prostate, reviewed in (Barton 2005). HIL-6 increased the number of 
mammospheres when added to the sphere medium. The number of spheres 
increased with the increase in the concentration of HIL-6 until 20 ng/ml. The number 
mammospheres reduced at 50 ng/ml. It could be assumed that the reduction of 
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spheres at 50 ng/ml was due to the fusion of spheres close to each other. However, 
this was not the case. The reduction in sphere numbers may have been due to the 
high concentration of HIL-6 which reduced the sphere forming efficiency of MECs. 
We therefore found 20 ng/ml HIL-6 to be optimal for sphere culture. GRO-α on the 
other hand is a CXC chemokine belongs to IL-8 family of cytokines and signals 
through its chemokine receptor CXCR2 activating MAPK through PI3K-Ras-Raf 
pathway. GRO-α is secreted by different cell types including melanoma cells, 
epithelial cells, neutrophils and macrophages. This chemokine is also involved in 
inflammation and wound healing (Luan, Shattuck-Brandt et al. 1997; Wang, 
Hendricks et al. 2006) and was also shown to play a role in melanoma and 
esophageal tumor progression (Luan, Shattuck-Brandt et al. 1997; Wang, Hendricks 
et al. 2006). GRO-α has a mitogenic effect on the neighboring premalignant epithelial 
cells and is a known potent epithelial cell growth factor (Coppe, Patil et al. 2010). 
Adding GRO-α to MECs in culture increased the number of mammospheres. The 
effect of GRO-α was as significant as HIL-6 had on MECs (figure 10). Both cytokines 
play a role in proliferation albeit acting through different growth promoting pathways. 
Therefore, addition of these two factors to the mammosphere culture resulted in an 
increased number of spheres when compared to either factor added alone. Further, 
when tested for their ability to induce sphere formation on fibroblasts, GRO-α and 
HIL-6 did not induce any sphere formation from freshly isolated mammary fibroblasts 
but the fibroblast cell lines did form spheres. Fibroblast cell lines have been cultured 
for years and may have evolved and adapted to survive even in suspension cultures. 
More importantly, the cytokines HIL-6 and GRO-α did not influence sphere formation 
in freshly isolated fibroblasts leading to false positives. In the context of the BM this 
was very crucial. Since, BM is a mesenchymal organ, it was essential that HIL-6 and 
GRO-α did not induce sphere formation in BM stromal or mesenchymal cells. These 
cytokines were therefore considered ideal in culturing DCCs in vitro. 
 
4.1.2. Bone marrow DCC culture 
Mammosphere conditions optimized for mammary epithelial sphere culture were 
tested to examine if these conditions could activate bone marrow DCC from BALB-
neuT. Bone marrow DCCs in BALB-neuT express Her2 (Husemann, Geigl et al. 
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2008) and also EpCAM. Studies in BALB-neuT have identified Sca-1 (stem cell 
antigen-1) expressing cells enriched with tumor forming potential (Grange, Lanzardo 
et al. 2008). In yet another breast cancer mouse model carrying polyomavirus 
middle-T oncogene, a subpopulation of the DCCs that were largely responsible for 
dissemination and metastasis were found expressing Sca-1 (Weng, Penzner et al. 
2012). Therefore, the bone marrow cells of BALB-neuT were enriched for Sca-1 in 
addition to EpCAM and Her2 (EHS) and thereby the DCCs in the BM confirmed by 
CK8/18. BALB-neuT BM cells either un-enriched or enriched for EHS cultured in the 
mammosphere medium failed to initiate growth in the DCCs. Although, the number of 
CK+ cells, identifying the DCCs, increased after enrichment with EHS they did not 
grow in the presence of GRO-α and HIL-6. Serum contains many factors that induce 
growth in cells and is routinely used in cell culture and, RPMI is a routine cell culture 
medium known to favor the growth of epithelial cells (Azzi, Bruno et al. ; Bussolati, 
Bruno et al. 2008). Since DCCs are epithelial derived, the BM cells were cultured in 
RPMI and FCS however, these conditions also could not trigger growth in DCCs. 
Even after 6 weeks in culture the DCCs failed to proliferate under these conditions. In 
conclusion, the conditions optimal for mammosphere formation from mammary 
epithelial cells are not optimal for DCC activation. Experiments evaluating the effect 
of BM in mammary epithelial cells (MEC) revealed that both BALB/c and BALB-neuT 
BM suppressed the growth of MECs. This suppressive effect however, was more 
significant in the presence of TBM than NSG BM cells on MECs. The suppressive 
effect of TBM and NBM conditioned medium on MECs suggests a role for BM cell 
secreted factors. It also suggests that the suppressive effect may not be a response 
of TBM cells due to the presence of DCCs or primary tumor in the BM but an innate 
property of the BM as NBM also had a similar effect on TMECs. NSG mice are 
deficient in mature T cells, B cells and natural killer cells and in several cytokine 
pathways (Shultz, Schweitzer et al. 1995; Shultz, Lyons et al. 2005). It has been 
reported that some of the immune cells secrete cytokines which exert a suppressive 
effect on the epithelial cells, especially the T-cells, like TGFβ, IFN, Oncostatin M and  
other factors (Huse, Quann et al. 2008). Since BM from NSG mice are deficient in T-
cells, TMEC growth was not as affected as observed in NBM or TBM probably 
because they lacked secreted factors from T cells with growth inhibitory effect. 
Sphere forming assay is a method used for enriching stem/progenitor cells, however 
this assay may not be suitable to activate quiescent cells resting in a G0 state. In one 
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of the studies published, quiescent neural stem cells were unable to form spheres in 
standard culture conditions and it was suggested that this could be due to the 
absence of key components of an in vivo niche that is required to activate the 
dormant stem cells (Pastrana, Silva-Vargas et al. 2011). Another possible 
explanation why DCCs were incapable of forming spheres in the mammosphere 
conditions could be that the in vitro conditions to activate DCCs may have lacked the 
key components of an in vivo niche. 
Our results from coculture suggest that DCCs proliferate in the presence of primary 
mammary epithelial cells in direct co-cultures or in the presence of tumor cells in 
transwells. In the first instance, the activation of DCC in the cocultures could be 
attributed to cell-cell interactions and possibly through gap junctions. Gap junctions 
not only connect the neighboring cells but also aid in diffusion of small molecules  
such as amino acids, ions and nucleotides (Lampe and Lau 2004). In breast cancer, 
gap junctional intercellular communication has been shown to play an important role 
in providing cross-talk between MECs and cells in their surrounding 
microenvironment (El-Saghir, El-Habre et al. 2011). Connexins which form gap 
junctions not only act as channels between neighboring cells but also as signal 
complexes with a crucial role in regulating cell function and transformation. However, 
there is a caveat that goes along with the co-cultures, that is too many PKH26+ 
spheres. Since contact between the cells cannot be avoided in co-cultures, spheres 
containing both DCC and NMEC cells are possible leading to false positives. 
In a transwell assay, DCCs and tumor cells were separated by a membrane with a 
pore size of 0.4 µm which allows only soluble secreted factors to pass through 
thereby preventing any intercellular communication. In this case, the activation of 
DCCs could have been through factors secreted by tumor cells of both TMEC and 
TUBO. Tumor cells are known to secrete many factors with proliferative effect on 
other cells. Proteomic studies of tissue interstitial fluids from breast tissue have 
shown that primary tissue secretes several cytokines which have an influence on cell 
proliferation. In tumor interstitial fluids, the secreted factor concentrations were higher 
in comparison to the normal breast tissue for some of the cytokines which are 
potential mitogens (Celis, Gromov et al. 2004). So, activation of DCCs in transwells 
was due to the factors secreted by TMEC or TUBO cells with growth inducing effect. 
Surprisingly, the normal mammary cells failed to activate DCC in a transwell 
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condition. Activation of DCCs by NMEC may require either 1) cell-cell interactions or 
2) factors secreted by the cells in higher concentrations.  
It was shown that during EMT epithelial markers like cytokeratins and EpCAM are 
down regulated in disseminating or circulating cancer cells (Mikolajczyk, Millar et al. 
2011; Gorges, Tinhofer et al. 2012). According to these studies, the number of DCCs 
could be higher than those detected by CK staining. However, our data suggests 
otherwise (table 8).  In transwell cultures the number of DCC derived spheres never 
exceeded the number of CK8/18 positive cells detected per million EpCAM, Her2 or 
Sca-1 enriched cells. These results are still preliminary and need to be examined 
further. 
 
4.2. Functional and molecular characterization of the in vitro activated DCCs 
Although DCC presence in the BM predicts poor outcome, not all DCCs are capable 
of initiating metastasis (Klein 2009) . Proliferation of DCCs in vitro does not imply that 
they are tumorigenic. However, the in vitro proliferating DCC spheres were 
tumorigenic in vivo suggesting that a population of activated DCCs had tumor 
initiating cells in the spheres that were transplanted in mice. The cells isolated from 
the in vivo tumors when cultured could expand in vitro in routine cell culture 
conditions to generate continuous cell lines.  RPMI + 10% FCS has been used by 
many groups especially to maintain epithelial cells. RPMI was shown to favor the 
growth of epithelial cells. In human renal cell carcinomas, when CD105+ cells were 
cultured in RPMI + 10% FCS they differentiated in to epithelial cells confirmed by 
expression of epithelial markers CK7, pan CK and E-cadherin (Azzi, Bruno et al. 
2011). DCC cell lines were generated by combining low centrifugation speeds for 
epithelial cell isolation (see materials and methods) and serum-free medium for 
eliminating stromal or fibroblast contamination (Kulkarni and McCulloch 1994). 
Morphological examination of the DCC cell lines generated contained minimal 
stromal cell contamination and CK8/18 and Her2 staining of the cells was 
comparable to CK8/18 staining in TUBO cells. TUBO cell line is an epithelial cell line 
derived from primary tumors of BALB-neuT and is positive for both CK8/18 and Her2. 
The DCC cell lines showed cobblestone morphology in culture growing as tight 
compact colonies, similar to TUBO cell line cultures, typical for epithelial cell lines in 
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culture. The tumors, the isolated tumor cells and the cell lines expressed CK8/18 
confirming their epithelial identity moreover, the presence of Her2 transgene in 
spheres and its expression in tumors and cell lines is an evidence for their DCC 
origin. Array CGH of DCC cell lines showed that they shared a few aberrations with 
TUBO cells. However, many genomic aberrations were unique to the DCC cell lines. 
The DCC cell lines were heterogeneous in their aberrant genomic profile. Cell lines 
derived from DCCs propagated in the presence of TUBO shared deletions on 
chromosome 4 and 14 with TUBO cells. On the other hand DCC cell lines 90-17 and 
4072 cell lines were derived from DCCs cultured in the presence TMECs were 
different to the rest of the DCC cell lines. Cell line 90-17 established from tumors 
generated by sub-cutaneous and 4072 from mammary fat pad transplantation of 
DCC spheres. DCC cell line 4072 was highly aberrant with aberrations seen on all 
the chromosomes with only one deletion on chromosome 4. Cells from 90-17 were 
quite different from 4072 and were less aberrant but deletion on chromosome 4 was 
common to both the cell lines. Cluster analysis showed that, 4072 and 90-17 were 
closer to each other and to 3940 and 3941 than 3942 and 3943. Furthermore, 3940, 
3943, 4072 and 90-17 were grouped together with TUBO. The DCC cell lines 3940 
and 3943 were closer to TUBO than 4072 and 90-17 while 3941 and 3942 were 
clustered in two separate groups and were away from the rest of the cell lines 
suggesting they are different from TUBO and other DCC derived cell lines. TUBO cell 
line was established from the primary tumors of BALB-neuT. Since DCCs are also 
derived from primary tumors of BALB-neuT, it is possible that a few aberrations are 
shared between the TUBO and the DCC cell lines.  
The DCC cell lines were derived from transplanted mice which had metastasis 
representing M1 stage of breast cancer, where one could argue that the DCCs were 
already in a proliferating state and hence were able to propagate in vitro and in vivo. 
However, DCCs from 8 week old BALB-neuT, representing M0 stage, when cultured 
in the presence of TMECs in a transwell were also able to proliferate and form 
spheres. Unfortunately, the mice transplanted with the DCC spheres of BALB-neuT 
mouse died of lymphoma preventing us from verifying their ability to initiate tumors in 
vivo. Still, BALB-neuT BM sphere shared some aberrations with TUBO and the DCC 
cell lines, especially on chromosomes 4 and 14. The aberrant genomic profile 
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indicates that the sphere has tumor cells but their tumorigenic ability still requires to 
be validated. 
It was unfortunate that the mouse injected with DCC spheres died of lymphoma and 
in vivo malignancy of the spheres could not be evaluated. Array CGH performed on 
one of the DCC spheres showed an aberrant genomic profile. Furthermore, the DCC 
sphere shared aberrations on chromosomes 4 and 14 with TUBO and the DCC cell 
lines, 3940, 3941, 3942 and 3943. This suggests that sphere contained tumor cells 
but their tumorigenic ability still needs to be evaluated. 
Together, in the current doctoral project we have shown that the conditions optimal 
for the growth of mammospheres in vitro are not optimal for in vitro propagation of 
bone marrow DCC. This study shows that 1) bone marrow has a suppressive effect 
on mammary cancer cells and 2) BM derived disseminated cancer cells from the 
mouse can be propagated in vitro in the presence of tumor cells. We could also show 
that the DCC activation could be mediated through tumor cell secreted factors in a 
transwell assay. The activated DCCs were tumorigenic in vivo, could further expand 
in vitro as cell lines and displayed an aberrant genomic profile suggesting that these 
were tumor cells.  
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